WO2022259204A1 - O-linked thiadiazolyl compounds as dna polymerase theta inhibitors - Google Patents

O-linked thiadiazolyl compounds as dna polymerase theta inhibitors Download PDF

Info

Publication number
WO2022259204A1
WO2022259204A1 PCT/IB2022/055384 IB2022055384W WO2022259204A1 WO 2022259204 A1 WO2022259204 A1 WO 2022259204A1 IB 2022055384 W IB2022055384 W IB 2022055384W WO 2022259204 A1 WO2022259204 A1 WO 2022259204A1
Authority
WO
WIPO (PCT)
Prior art keywords
independently selected
pharmaceutically acceptable
alkyl
acceptable salt
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2022/055384
Other languages
English (en)
French (fr)
Inventor
Paul A. Barsanti
Firoz Ali JAIPURI
Daniel Lee Severance
Chenbo WANG
Kevin J. Duffy
Brian G. LAWHORN
Nicholas David ADAMS
Janos Botyanszki
Michael G. Darcy
Terence J. Kiesow
John J. MCATEE
Cuthbert Martyr
Alexander BUITRAGO SANTANILLA
Xinrong Tian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property No 4 Ltd
Ideaya Biosciences Inc
Original Assignee
GlaxoSmithKline Intellectual Property No 4 Ltd
Ideaya Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2023576009A priority Critical patent/JP2024522373A/ja
Priority to CA3222078A priority patent/CA3222078A1/en
Priority to KR1020247000980A priority patent/KR20240044412A/ko
Priority to MX2023014665A priority patent/MX2023014665A/es
Priority to AU2022289762A priority patent/AU2022289762B2/en
Priority to EP22735990.8A priority patent/EP4352055A1/en
Priority to US18/567,687 priority patent/US20240287080A1/en
Priority to IL308912A priority patent/IL308912A/en
Application filed by GlaxoSmithKline Intellectual Property No 4 Ltd, Ideaya Biosciences Inc filed Critical GlaxoSmithKline Intellectual Property No 4 Ltd
Priority to CN202280054416.4A priority patent/CN117794927A/zh
Priority to BR112023025245A priority patent/BR112023025245A2/pt
Publication of WO2022259204A1 publication Critical patent/WO2022259204A1/en
Priority to CONC2023/0017082A priority patent/CO2023017082A2/es
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Definitions

  • DNA repair deficient cancers often become dependent on backup DNA repair pathways, which present an “Achilles heel” that can be targeted to eliminate cancer cells, and is the basis of synthetic lethality.
  • Synthetic lethality is exemplified by the success of poly (ADP-ribose) polymerase (PARP) inhibitors in treating BRCA-deficient breast and ovarian cancers (Audeh M. W., et al., Lancet (2010); 376 (9737): 245-51).
  • PARP poly (ADP-ribose) polymerase
  • DNA damage repair processes are critical for genome maintenance and stability, among which, double strand breaks (DSBs) are predominantly repaired by the nonhomologous end joining (NHEJ) pathway in G1 phase of the cell cycle and by homologous recombination (HR) in S-G2 phases.
  • NHEJ nonhomologous end joining
  • HR homologous recombination
  • a less addressed alternative end-joining (alt-EJ), also known as microhomology-mediated end-joining (MMEJ) pathway is commonly considered as a “backup” DSB repair pathway when NHEJ or HR are compromised.
  • MMEJ microhomology-mediated end-joining
  • Numerous genetic studies have highlighted a role for DNA polymerase theta (Ro ⁇ q, encoded by POLQ) in stimulating MMEJ in higher organisms (Chan S. H., et al., PLoS Genet.
  • PolO is distinct among human DNA polymerases, exhibiting not only a C-terminal DNA polymerase domain but also an N-terminal helicase domain separated by a long and lesser- conserved central domain of unknown function beyond Rad51 binding (Seki eta. Al, 2003, Shima et al 2003; Yousefzadeh and Wood 2013).
  • the N-terminal ATPase/helicase domain belongs to the HELQ class of SF2 helicase super family.
  • HRD homologous recombination deficient
  • the helicase domain of PolO causes suppression of HR pathway through disruption of Rad51 nucleoprotein complex formation involved in initiation of the HR-dependent DNA repair reactions following ionizing radiation. This anti-recombinase activity of PolO promotes the alt-EJ pathway.
  • the helicase domain of PolO contributes to microhomology-mediated strand annealing (Chan SH et al., PLoS Genet. (2010); 6: el001005; and Kawamura K et al., Int. J. Cancer (2004); 109: 9-16).
  • PolO efficiently promotes end-joining in alt-EJ pathway by employing this annealing activity when ssDNA overhangs contain >2 bp of microhomology (Kent T., et al., Elife (2016); 5: el3740), and Kent T., et al., Nat. Struct. Mol. Biol. (2015); 22: 230-237).
  • This reannealing activity is achieved through coupled actions of Rad51 interaction followed by ATPase- mediated displacement of Rad51 from DSB damage sites.
  • the primer strand of DNA can be extended by the polymerase domain of PolO.
  • compositions comprising such compounds and methods of treating and/or preventing diseases treatable by inhibition of PolO such as cancer, including homologous recombination (HR) deficient cancers.
  • HR homologous recombination
  • a compound of Formula (I), or a pharmaceutically acceptable salt thereof wherein ring A, Ar 1 , R 1 , R 2 , R 3 , and subscripts n and m have the meanings provided hereinbelow.
  • pharmaceutical compositions comprising a compound of Formula (I) or a subembodiment or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient.
  • a method for treating and/or preventing a disease characterized by overexpression of PolO in a patient comprising administering to the patient a therapeutically effective amount of a compound of Formula (I) or a subembodiment or a pharmaceutically acceptable salt thereof.
  • the patient is in recognized need of such treatment.
  • the compound of Formula (I) or a subembodiment or a pharmaceutically acceptable salt thereof is administered in a pharmaceutical composition.
  • the disease is a cancer.
  • a method for treating and/or preventing a homologous recombinant (HR) deficient cancer in a patient comprising administering to the patient a therapeutically effective amount of a compound of Formula (I) or a subembodiment or a pharmaceutically acceptable salt thereof.
  • the patient is in recognized need of such treatment.
  • the compound of Formula (I) or a subembodiment or a pharmaceutically acceptable salt thereof is administered in a pharmaceutical composition.
  • a method for inhibiting DNA repair by Ro ⁇ q in a cancer cell comprising contacting the cell with an effective amount of a compound of Formula (I) or a subembodiment or a pharmaceutically acceptable salt thereof.
  • the cancer is HR deficient cancer.
  • a method for treating and/orpreventingng a cancer in a patient wherein the cancer is characterized by a reduction or absence of BRCA gene expression, the absence of the BRCA gene, or reduced function of BRCA protein, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a subembodiment or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutical composition.
  • a compound of Formula (I) or a subembodiment or a pharmaceutically acceptable salt thereof for inhibiting DNA repair by PolO in a cell In one embodiment, the cell is HR deficient cell.
  • a compound of Formula (I) or a subembodiment or a pharmaceutically acceptable salt thereof for use in the treatment and/or prevention of a disease in a patient, wherein the disease is characterized by overexpression of Ro ⁇ q.
  • a compound of Formula (I) or a subembodiment or a pharmaceutically acceptable salt thereof for use in the treatment and/or prevention of a cancer in a patient, wherein the cancer is characterized by a reduction or absence of BRCA gene expression, the absence of the BRCA gene, or reduced function of BRCA protein.
  • a compound of Formula (I) or a subembodiment or a pharmaceutically acceptable salt thereof for use in the treatment and/or prevention of a HR deficient cancer in a patient.
  • a compound of Formula (I) or a subembodiment or a pharmaceutically acceptable salt thereof for use in the treatment and/or prevention of a cancer that is resistant to poly(ADP-ribose) polymerase (PARP) inhibitor therapy in a patient.
  • PARP poly(ADP-ribose) polymerase
  • cancers resistant to PARP-inhibitors include, but are not limited to, breast cancer, ovarian cancer, lung cancer, bladder cancer, liver cancer, head and neck cancer, pancreatic cancer, gastrointestinal cancer, and colorectal cancer.
  • a compound of Formula (I) or a subembodiment or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment or prevention of cancer, wherein the cancer is characterized by a reduction or absence of BRCA gene expression, the absence of the BRCA gene, or reduced function of BRCA protein.
  • a compound of Formula (I) or a subembodiment or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment or prevention of a HR deficient cancer.
  • a compound of Formula (I) or a subembodiment or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of cancer that is resistant to poly(ADP-ribose) polymerase (PARP) inhibitor therapy in a patient.
  • PARP poly(ADP-ribose) polymerase
  • the cancer is lymphoma, rhabdoid tumor, multiple myeloma, uterine cancer, gastric cancer, peripheral nervous system cancer, rhabdomyosarcoma, bone cancer, colorectal cancer, mesothelioma, breast cancer, ovarian cancer, lung cancer, fibroblast cancer, central nervous system cancer, urinary tract cancer, upper aerodigestive cancer, leukemia, kidney cancer, skin cancer, esophageal cancer, and pancreatic cancer (data from large scale drop out screens in cancer cell lines indicate that some cell lines from the above cancers are dependent on polymerase theta for proliferation http s : //depmap . org/portal/) .
  • a HR-deficient cancer is breast cancer.
  • Breast cancer includes, but is not limited to, lobular carcinoma in situ (LCIS), a ductal carcinoma in situ (DCIS), an invasive ductal carcinoma (IDC), inflammatory breast cancer, Paget disease of the nipple, Phyllodes tumor, Angiosarcoma, adenoid cystic carcinoma, low- grade adenosquamous carcinoma, medullary carcinoma, mucinous carcinoma, papillary carcinoma, tubular carcinoma, metaplastic carcinoma, micropapillary carcinoma, mixed carcinoma, or another breast cancer, including but not limited to triple negative, HER positive, estrogen receptor positive, progesterone receptor positive, HER and estrogen receptor positive, HER and progesterone receptor positive, estrogen and progesterone receptor positive, and HER and estrogen and progesterone receptor positive.
  • HR-deficient cancer is ovarian cancer.
  • Ovarian cancer includes, but is not limited to, epithelial ovarian carcinomas (EOC), maturing teratomas, dysgerminomas, endodermal sinus tumors, granulosa-theca tumors, Sertoli -Leydig cell tumors, and primary peritoneal arcinoma.
  • any definition herein may be used in combination with any other definition to describe a composite structural group.
  • the trailing element of any such definition is that which attaches to the parent moiety.
  • the composite group alkoxyalkyl means that an alkoxy group is attached to the parent molecule through an alkyl group.
  • alkyl by itself or as part of another substituent, means, unless otherwise stated, a saturated straight or branched chain hydrocarbon radical, having the number of carbon atoms designated (i.e. Ci- 8 means one to eight carbons).
  • Alkyl can include any number of carbons, such as Ci-2, Ci-3, CM, C1-5, Ci-6, C1-7, Ci-s, C1-9, Ci-10, C2-3, C2-4, C2-5, C2-6, C3-4, C 3 -5, C 3 -6, C 4-5 , C 4-6 and C 5-6 .
  • alkyl groups include methyl, ethyl, n-propyl, isopropyl, n- butyl, t-butyl, isobutyl, sec -butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like.
  • alkylene refers to a straight or branched, saturated, aliphatic radical having the number of carbon atoms indicated, and linking at least two other groups, i.e., a divalent hydrocarbon radical. The two moieties linked to the alkylene can be linked to the same atom or different atoms of the alkylene group.
  • a straight chain alkylene can be the bivalent radical of -(CH2) n-, where n is 1, 2, 3, 4, 5 or 6.
  • Representative alkylene groups include, but are not limited to, methylene, ethylene, propylene, isopropylene, butylene, isobutylene, sec -butylene, pentylene, hexylene, and the like.
  • alkoxy refers to an alkyl group having an oxygen atom that connects the alkyl group to the point of attachment: alkyl-O-.
  • alkoxy groups can have any suitable number of carbon atoms, such as Ci- 6 , and can be straight or branced.
  • Alkoxy groups include, for example, methoxy, ethoxy, propoxy, iso-propoxy, butoxy, 2-butoxy, iso-butoxy, sec -butoxy, tert-butoxy, pentoxy, hexoxy, etc.
  • cyano by itself or as part of another substituent, refers to a moiety having the formula -CN, i.e., a carbon atom triple-bonded to nitrogen atom.
  • cycloalkyl refers to a saturated or partially unsaturated hydrocarbon ring having the indicated number of ring atoms (e.g., C3-6 cycloalkyl). Cycloalkyl can include any number of carbons, such as C3-6, C4-6, C5-6, C3-8, C4-8, C5-8, Ces, C3-9, and C3-10. Partially unsaturated cycloalkyl groups have one or more double or triple bonds in the ring, but cycloalkyl groups are not aromatic. Saturated monocyclic cycloalkyl rings include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cyclooctyl.
  • cycloalkyloxy refers to a cycloalkyl group having an oxygen atom that connects the cycloalkyl group to the point of attachment: cycloalkyl-O-.
  • the cycloalkyl group is as defined herein.
  • spirocyclyl or “spirocycloalkyl” refer to a saturated or partially unsaturated bicyclic ring having 6 to 12 ring atoms, where the two rings are connected via a single carbon atom (also called the spiroatom).
  • Partially unsaturated spirocycloalkyl groups have one or more double or triple bonds in the ring, but spirocycloalkyl groups are not aromatic.
  • Representative examples include, but are not limited to, spiro[3.3]heptane, spiro[4.4]nonane, spiro[3.4]octane, and the like.
  • bridged cycloalkyl means a monocyclic 6- to 11-membered hydrocarbon radical in which two non-adjacent ring atoms are linked by a (CH2) n group where n is 1 to 3 (also referred to herein as the bridging group).
  • Examples of bridged cycloalkyl include but are not limited to bicyclo[2.2.1]heptane and bicyclo[2.2.2]octane.
  • the term is also meant to include bridged polycyclic hydrocarbon groups such as adamantane.
  • heterocycloalkyl refers to a saturated or partially unsatured monocyclic ring having the indicated number of ring vertices (e.g., a 3- to 7-membered ring) and having from one to five heteroatoms selected from N, O, and S as ring vertices.
  • Partially unsaturated heterocycloalkyl groups have one or more double or triple bonds in the ring, but heterocycloalkyl group are not aromatic.
  • Heterocycloalkyl groups can include any number of ring atoms, such as, 3 to 6, 4 to 6, 5 to 6, 3 to 7, 4 to 7, or 5 to 7 ring members.
  • heterocycloalkyl groups any suitable number of heteroatoms can be included in the heterocycloalkyl groups, such as 1, 2, 3, or 4, or 1 to 2, 1 to 3, 1 to 4, 2 to 3, 2 to 4, or 3 to 4.
  • Non-limiting examples of heterocycloalkyl groups include pyrrolidine, imidazolidine, pyrazolidine, butyrolactam, valerolactam, imidazolidinone, hydantoin, dioxolane, phthalimide, piperidine, 1,4-dioxane, morpholine, thiomorpholine, thiomorpholine-S-oxide, thiomorpholine-S,S-oxide, piperazine, pyran, pyridone, 3-pyrroline, thiopyran, pyrone, tetrahydrofuran, tetrahydrothiophene, quinuclidine, and the like.
  • a heterocycloalkyl group can be attached to the remainder of the
  • bicyclic heterocycloalkyl or "bicyclic heterocyclyl” refers to a saturated or partially unsaturated fused bicyclic ring having the indicated number of ring vertices (e.g., a 6- to 12-membered ring) and having from one to five heteroatoms selected from N, O, and S as ring vertices.
  • Partially unsaturated bicyclic heterocycloalkyl groups have one or more double or triple bonds in the ring, but bicyclic heterocycloalkyl groups are not aromatic.
  • Bicyclic heterocycloalkyl groups can include any number of ring atoms, such as, 6 to 8,
  • heterocycloalkyl groups 6 to 9, 6 to 10, 6 to 11, or 6 to 12 ring members.
  • Any suitable number of heteroatoms can be included in the heterocycloalkyl groups, such as 1, 2, 3, or 4, or 1 to 2, 1 to 3, 1 to 4, 2 to 3, 2 to 4, or 3 to 4.
  • Non-limiting examples of bicyclic heterocycloalkyl groups include decahydro-l,5-naphthyridine, octahydropyrrolo[l,2-a]pyrazine, and the like.
  • bridged heterocyclyl or “bridged heterocycloalkyl” refers to a heterocycloalkyl ring (having 5 to 8 ring vertices) in which two non-adjacent ring atoms are linked by a (CRR’) n group where n is 1 to 3 and each R is independently H or methyl (also may be referred to herein as “bridging” group).
  • Bridged heterocyclyl groups have one to five heteroatoms selected from N, O, and S as ring vertices.
  • the heteroatom ring vertices can be in both the heterocycloalkyl ring portion as well as the bridging group. When in the bridging group, the heteroatom replaces a CRR’ group. Examples include, but are not limited to, 2- azabicyclo[2.2.2]octane, quinuclidine, 7-oxabicyclo[2.2.1]heptane, and the like.
  • spiroheterocyclyl or “spiroheterocycloalkyl” refer to a saturated or partially unsaturated bicyclic ring having 6 to 12 ring atoms, where the two rings are connected via a single carbon atom (also called the spiroatom).
  • Spiroheterocyclyl groups have from one to five heteroatoms selected from N, O, and S as ring vertices, and the nitrogen atom(s) are optionally quatemized.
  • Partially unsaturated spiroheterocycloalkyl groups have one or more double or triple bonds in the ring, but spiroheterocycloalkyl groups are not aromatic.
  • Representative examples include, but are not limited to, 4-oxaspiro[2.4]heptane, 2,6- diazaspiro[3.3]heptane, 2,6-diazaspiro[3.4]octane, 2-azaspiro[3.4]octane, 2-azaspiro
  • halo or halogen, by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom.
  • haloalkyl refers to alkyl, as defined above, where some or all of the hydrogen atoms are replaced with halogen atoms.
  • alkyl group haloalkyl groups can have any suitable number of carbon atoms, such as Ci-6.
  • Ci-6 the term “Ci -4 haloalkyl” is meant to include trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.
  • haloalkoxy refers to an alkoxy group where some or all of the hydrogen atoms are substituted with halogen atoms.
  • haloalkoxy groups can have any suitable number of carbon atoms, such as Ci- 6 , and can be straight or branced, and are substituted with 1, 2, 3, or more halogens. When all the hydrogens are replaced with a halogen, for example by fluorine, the compounds are per-substituted, for example, perfluorinated.
  • Haloalkoxy includes, but is not limited to, trifluoromethoxy, 2,2,2,-trifluoroethoxy, perfluoroethoxy, etc.
  • hydroxyalkyl refers to an alkyl group where one of the hydrogen atoms is substituted with a hydroxy (-OH) group.
  • hydroxyalkyl groups can have any suitable number of carbon atoms, such as Ci- 6 , and can be straight or branced.
  • Hydroxyalkyl groups include, for example, hydroxymethyl, 1-hydroxylethyl, 2-hydroxyethyl, 2-hydroxylpropan-2-yl, etc.
  • aryl means, unless otherwise stated, a polyunsaturated, typically aromatic, hydrocarbon group which can be a single ring or multiple rings (up to three rings) which are fused together or linked covalently.
  • Non-limiting examples of aryl groups include phenyl, naphthyl and biphenyl.
  • heteroaryl refers to a 5 - to 10-membered aromatic ring (or fused ring system) that contains from one to five heteroatoms selected from N, O, and S.
  • Heteroaryl groups can include any number of ring atoms, such as, 5 to 6, 5 to 8, 6 to 8, 6 to 9, 9 to 10, 9, 10 ring members. Any suitable number of heteroatoms can be included in the heteroaryl groups, such as 1, 2, 3, 4, or 5, or 1 to 2, 1 to 3, 1 to 4, 1 to 5, 2 to 3, 2 to 4, 2 to 5, 3 to 4, or 3 to 5.
  • a heteroaryl group can be attached to the remainder of the molecule through a heteroatom.
  • heteroaryl groups include pyridyl, pyridazinyl, pyrazinyl, pyrimindinyl, triazinyl, quinolinyl, quinoxalinyl, quinazolinyl, cinnolinyl, phthalazinyl, benzotriazinyl, purinyl, benzimidazolyl, benzopyrazolyl, benzotriazolyl, benzisoxazolyl, isobenzofuryl, isoindolyl, indolizinyl, benzotriazinyl, thienopyridinyl, thienopyrimidinyl, pyrazolopyrimidinyl, imidazopyridines, benzothiaxolyl, benzofuranyl, benzothienyl, indolyl, quinolyl, isoquinolyl, isothiazolyl, pyrazolyl, indazolyl, p
  • heteroatom is meant to include oxygen (O), nitrogen (N), sulfur (S).
  • salts are meant to include salts of the active compounds which are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein.
  • base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent.
  • salts derived from pharmaceutically-acceptable inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic, manganous, potassium, sodium, zinc and the like.
  • Salts derived from pharmaceutically-acceptable organic bases include salts of primary, secondary and tertiary amines, including substituted amines, cyclic amines, naturally- occuring amines and the like, such as arginine, betaine, caffeine, choline, N,N’- dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine and the like.
  • acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent.
  • pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, malonic, benzoic, succinic, suberic, fumaric, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, methane sulfonic, and the like.
  • salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, for example, Berge, S.M., et al, “Pharmaceutical Salts”, Journal of Pharmaceutical Science, 1977, 66, 1-19).
  • Certain specific compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.
  • the neutral forms of the compounds may be regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner.
  • the parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of the present invention.
  • Certain compounds of the present disclosure can exist in unsolvated forms as well as solvated forms, including hydrated forms.
  • the solvated forms are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention.
  • Certain compounds of the present invention may exist in multiple crystalline or amorphous forms. All potential physical forms are intended to be within the scope of the present invention.
  • Certain compounds of the present invention possess asymmetric carbon atoms (optical centers); the racemates, diastereomers, and individual isomers (e.g., separate enantiomers) are all intended to be encompassed within the scope of the present invention.
  • a stereochemical depiction it is meant to refer the compound in which one of the isomers is present and substantially free of the other isomer.
  • substantially free of another isomer indicates at least an 80/20 ratio of the two isomers, more preferably 90/10, or 95/5 or more. In some embodiments, one of the isomers will be present in an amount of at least 99%.
  • the compounds of the present invention may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds.
  • Unnatural proportions of an isotope may be defined as ranging from the amount found in nature to an amount consisting of 100% of the atom in question.
  • the compounds may incorporate radioactive isotopes, such as for example tritium ( 3 H), iodine- 125 ( 125 I) or carbon- 14 ( 14 C), or non-radioactive isotopes, such as deuterium ( 2 H) or carbon-13 ( 13 C).
  • radioactive isotopes such as for example tritium ( 3 H), iodine- 125 ( 125 I) or carbon- 14 ( 14 C), or non-radioactive isotopes, such as deuterium ( 2 H) or carbon-13 ( 13 C).
  • isotopic variations can provide additional utilities to those described elsewhere within this application.
  • isotopic variants of the compounds of the invention may find additional utility, including but not limited to, as diagnostic and/or imaging reagents, or as cytotoxic/radiotoxic therapeutic agents. Additionally, isotopic variants of the compounds of the invention can have altered pharmacokinetic and pharmacodynamic characteristics which can contribute to enhanced safety, tolerability or efficacy during treatment. All isotopic variations of the compounds of the present invention, whether radioactive or not, are intended to be encompassed within the scope of the present invention.
  • administration refers to contact of, for example, an Ro ⁇ q modulator, a pharmaceutical composition comprising same, or a diagnostic agent to the subject, cell, tissue, organ, or biological fluid.
  • administration includes contact (e.g., in vitro or ex vivo) of a reagent to the cell, as well as contact of a reagent to a fluid, where the fluid is in contact with the cell.
  • treat refers to a course of action (such as administering a Ro ⁇ q modulator or a pharmaceutical composition comprising same) initiated after a disease, disorder or condition, or a symptom thereof, has been diagnosed, observed, and the like so as to eliminate, reduce, suppress, mitigate, or ameliorate, either temporarily or permanently, at least one of the underlying causes of a disease, disorder, or condition afflicting a subject, or at least one of the symptoms associated with a disease, disorder, condition afflicting a subject.
  • treatment includes inhibiting (e.g., arresting the development or further development of the disease, disorder or condition or clinical symptoms association therewith) an active disease.
  • in need of treatment refers to a judgment made by a physician or other caregiver that a subject requires or will benefit from treatment. This judgment is made based on a variety of factors that are in the realm of the physician’s or caregiver's expertise. For example, the patient has been diagonosed as having a disease linked to overexpression of Ro ⁇ q or a homologous recombination (HR) -deficient cancer.
  • HR homologous recombination
  • prevent refers to a course of action (such as administering an Ro ⁇ q modulator or a pharmaceutical composition comprising same) initiated in a manner (e.g., prior to the onset of a disease, disorder, condition or symptom thereof) so as to prevent, suppress, inhibit or reduce, either temporarily or permanently, a subject’s risk of developing a disease, disorder, condition or the like (as determined by, for example, the absence of clinical symptoms) or delaying the onset thereof, generally in the context of a subject predisposed to having a particular disease, disorder or condition.
  • in need of prevention refers to a judgment made by a physician or other caregiver that a subject requires or will benefit from preventative care. This judgment is made based on a variety of factors that are in the realm of a physician’s or caregiver’s expertise.
  • therapeutically effective amount refers to the administration of an agent to a subject, either alone or as part of a pharmaceutical composition and either in a single dose or as part of a series of doses, in an amount capable of having any detectable, positive effect on any symptom, aspect, or characteristic of a disease, disorder or condition when administered to the subject.
  • the therapeutically effective amount can be ascertained by measuring relevant physiological effects, and it can be adjusted in connection with the dosing regimen and diagnostic analysis of the subject’s condition, and the like.
  • measurement of the serum level of an Ro ⁇ q modulator (or, e.g., a metabolite thereof) at a particular time post-administration may be indicative of whether a therapeutically effective amount has been used.
  • modulate refers to the ability of a molecule (e.g., an activator or an inhibitor) to increase or decrease the function or activity of Ro ⁇ q, either directly or indirectly.
  • a modulator may act alone, or it may use a cofactor, e.g., a protein, metal ion, or small molecule. Examples of modulators include small molecule compounds and other bioorganic molecules.
  • the "activity" of a molecule may describe or refer to the binding of the molecule to a ligand or to a receptor; to catalytic activity; to the ability to stimulate gene expression or cell signaling, differentiation, or maturation; to antigenic activity; to the modulation of activities of other molecules; and the like.
  • proliferative activity encompasses an activity that promotes, that is necessary for, or that is specifically associated with, for example, normal cell division, as well as cancer, tumors, dysplasia, cell transformation, metastasis, and angiogenesis.
  • Certain compounds of the present disclosure can exist as tautomers and/or geometric isomers. All possible tautomers and cis and trans isomers, as individual forms and mixtures thereof are within the scope of this disclosure. For example, certain hydroxy substituted compounds may exist as as tautomers as shown below:
  • “Pharmaceutically acceptable carrier or excipient” means a carrier or an excipient that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes a carrier or an excipient that is acceptable for veterinary use as well as human pharmaceutical use. “A pharmaceutically acceptable carrier/excipient” as used in the specification and claims includes both one and more than one such excipient.
  • a wavy line that intersects a single, double or triple bond in any chemical structure depicted herein, represent the point attachment of the single, double, or triple bond to the remainder of the molecule.
  • a bond extending to the center of a ring e.g., a phenyl ring
  • a bond extending to the center of a ring is meant to indicate attachment at any of the available ring vertices.
  • Disease as used herein is intended to be generally synonymous, and is used interchangeably with, the terms “disorder, " “syndrome, “ and “condition” (as in medical condition), in that all reflect an abnormal condition of the human or animal body or of one of its parts that impairs normal functioning, is typically manifested by distinguishing signs and symptoms, and causes the human or animal to have a reduced duration or quality of life.
  • Patient is generally synonymous with the term "subject” and as used herein includes all mammals including humans. Examples of patients include humans, livestock such as cows, goats, sheep, pigs, and rabbits, and companion animals such as dogs, cats, rabbits, and horses. Preferably, the patient is a human.
  • “Inhibiting”, "reducing,” or any variation of these terms in relation of Ro ⁇ q includes any measurable decrease or complete inhibition to achieve a desired result. For example, there may be a decrease of about, at most about, or at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, or any range derivable therein, reduction of PolO activity compared to its normal activity.
  • homologous recombination refers to the cellular process of genetic recombination in which nucleotide sequences are exchanged between two similar or identical DNA.
  • HR deficient cancer refers to a cancer that is characterized by a reduction or absence of a functional HR repair pathway. HR deficiency may arise from absence of one or more HR-assocated genes or presence of one or more mutations in one or more HR-assocated genes.
  • HR-associated genes include BRCA1, BRCA2, RAD54, RAD51B, CtlP (Choline Transporter-Like Protein), PALB2 (Partner and Localizer of BRCA2), XRCC2 (X-ray repair complementing defective repair in Chinese hamster cells 2), RECQL4 (RecQ Protein-Like 4), BLM (Bloom syndrome, RecQ helicase-like), WRN (Wemer syndrome , one or more HR-assocated genes) Nbs 1 (Nibrin), and genes encoding Fanconi anemia (FA) proteins or FA-like genes e.g, FANCA, FANCB, FANCC, FANCD1 (BRCA2), FANCD2, FANCE, FANCF, FANCG, FANCI, FANJ (BRIP1), FANCL, FANCM, FANCN (RALB2), FANCP (SLX4), FANCS (BRCA1), RAD51C, and XPF.
  • FANCA Fanconi
  • Ro ⁇ q overexpression refers to the increased expression or activity of Ro ⁇ q in a diseases cell e.g., cancerous cell, relative to expression or activity of Ro ⁇ q in a normal cell (e.g., non-diseased cell of the same kind).
  • the amount of Ro ⁇ q can be at least 2-fold, at least 3-fold, at least 4- fold, at least 5- fold, at least 10-fold, or more relative to the PolO expression in a normal cell.
  • PolO cancers include, but are not limited to, breast, ovarian, cervical, lung, colorectal, gastric, bladder and prostate cancers.
  • ring A is selected from the group consisting of phenyl and a 5- to 6- membered heteroaryl ring having 1 to 4 heteroatoms independently selected from N, O, and S; the subscripts m and n are each independently 0 or 1 ;
  • R 1 is selected from the group consisting of Ci- 6 alkyl, halo, Ci- 6 haloalkyl, -X'-O-Ci ⁇ alkyl, Ci-6 haloalkoxy, -X'-cyano. -N0 2 , -C(0)0R a , -NR a C(0)R b , -X 1 -C(0)NR a R b , -X 1 - OH, C3-6 cycloalkyl, -X'-O- C3-6 cycloalkyl, Ci- 6 hydroxyalkynyl, -X'-NR a R b .
  • R 2 is selected from the group consisting of Ci- 6 alkyl, halo, Ci- 6 haloalkyl, Ci- 6 haloalkoxy, and
  • each X 1 is independently selected from a bond and C1-4 alkylene
  • X la is 3- to 6- membered heterocycloalkylene having 1 to 4 heteroatoms as ring vertices independently selected from N, O, and S, and R a and R b are independently selected from the group consisting of hydrogen, Ci- 6 alkyl, and Ci- 6 haloalkyl; and
  • Ar 1 is selected form the group consisting of phenyl, naphthyl, pyridin-2-one, and a 5- to 10- membered heteroaryl ring having 1 to 4 heteroatoms independently selected from N, O, and S, wherein Ar 1 is substituted with 0 to 4 R la substituents; each R la is independently selected from Ci- 6 alkyl, halo, Ci- 6 haloalkyl,
  • R 3 member (vii) is substituted with from 0 to 3 R 3b substituents selected from the group consisting of halo, C1-3 haloalkyl, Ci-6 haloalkoxy, -O-Ci-6 alkyl, cyano, -OH, - NR e R f ,
  • each X 3 is independently selected from a bond and CM alkylene
  • each R e and R f is independently selected from H, Ci- 6 alkyl, Ci- 6 haloalkyl, C3-6 cycloalkyl and -Ci-3alkylene-C3-6 cycloalkyl; or a pharmaceutically acceptable salt thereof.
  • ring A is selected from the group consisting of phenyl and a 5- to 10- membered heteroaryl ring having 1 to 4 heteroatoms independently selected from N, O, and S; the subscripts m and n are each independently 0 or 1 ;
  • R 1 is is selected from the group consisting of Ci- 6 alkyl, halo, Ci- 6 haloalkyl, -X'-O-C M alkyl,
  • R 2 is selected from the group consisting of Ci- 6 alkyl, halo, Ci- 6 haloalkyl, Ci- 6 haloalkoxy, and
  • each X 1 is independently selected from a bond and C alkylene
  • X la is 3- to 6- membered heterocycloalkylene having 1 to 4 heteroatoms as ring vertices independently selected from N, O, and S, and R a and R b are independently selected from the group consisting of hydrogen, Ci- 6 alkyl, and Ci- 6 haloalkyl; and Ar 1 is selected form the group consisting of phenyl, naphthyl, pyridin-2-one, and a 5- to 10- membered heteroaryl ring having 1 to 4 heteroatoms independently selected from N, O, and S, wherein Ar 1 is substituted with 0 to 4 R la substituents; each R la is is independently selected from Ci- 6 alkyl, halo, Ci- 6 haloalkyl,
  • each R 3 member of (i) through (v) is substituted with 0 to 4 R 3a substituents, each of which is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halo, Ci-6 haloalkyl, Ci- 6 haloalkoxy, -X 3 -0-CI- 6 alkyl, -X 3 -OH, -NR e R f , -ONO2, 4- to 6-member heterocycloalkyl having 1 to 4 heteroatoms as ring vertices independently selected from N, O, and S, -NR e C(0)R f , -X 3 -NR e R f ,-X 3 -cyano, and oxo; and R 3 member (vii) is substituted with from 0 to 3 R 3b substituents selected from the group consisting of halo, C1-3 haloalkyl
  • ring A is selected from the group consisting of phenyl and a 5- to 10- membered heteroaryl ring having 1 to 4 heteroatoms independently selected from N, O, and S; the subscripts m and n are each independently 0 or 1 ;
  • R 1 is selected from the group consisting of Ci- 6 alkyl, halo, Ci- 6 haloalkyl, -X'-O-C M alkyl, Ci-6 haloalkoxy, -X'-cyano, -N0 2 , -C(0)OR a , -NR a C(0)R b , -X 1 -C(0)NR a R b , -X 1 - OH, C3-6 cycloalkyl, -X'-O- C3-6 cycloalkyl, Ci- 6 hydroxyalkynyl, -X'-NR a R b .
  • R 2 is selected from the group consisting of Ci- 6 alkyl, halo, Ci- 6 haloalkyl, Ci- 6 haloalkoxy, and
  • each X 1 is independently selected from a bond and CM alkylene
  • X la is 3- to 6- membered heterocycloalkylene having 1 to 4 heteroatoms as ring vertices independently selected from N, O, and S, and R a and R b are independently selected from the group consisting of hydrogen, Ci- 6 alkyl, and Ci-6 haloalkyl; and
  • Ar 1 is selected form the group consisting of phenyl, naphthyl, pyridin-2-one, and a 5- to 10- membered heteroaryl ring having 1 to 4 heteroatoms independently selected from N, O, and S, wherein Ar 1 is substituted with 0 to 4 R la substituents; each R la is independently selected from Ci-6 alkyl, halo, Ci-6 haloalkyl,
  • each R 3 member of (i) through (v) is substituted with 0 to 4 R 3a substituents, each of which is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halo, Ci-6 haloalkyl, Ci- 6 haloalkoxy, -X 3 -0-C I-6 alkyl, -X 3 -OH, -NR e R f , -ONO2, 4- to 6-member heterocycloalkyl having 1 to 4 heteroatoms as ring vertices independently selected from N, O, and S, -NR e C(0)R f , -X 3 -NR e R f ,-X 3 -cyano, and oxo; and R 3 member (vii) is substituted with from 0 to 3 R 3b substituents selected from the group consisting of halo, C1-3 haloalkyl
  • each X 3 is independently selected from a bond and C M alkylene
  • each R e and R f is independently selected from H, Ci- 6 alkyl, Ci- 6 haloalkyl, C3-6 cycloalkyl and -Ci-3alkylene-C3-6 cycloalkyl; or a pharmaceutically acceptable salt thereof.
  • the compounds of Formula I are other than
  • the compounds of Formula I are other than those where ring A is In some embodiments, the compounds of Formula I are other than those where ring A is indole.
  • ring A is selected from the group consisting of phenyl and a 5- to 10- membered heteroaryl ring having 1 to 4 heteroatoms independently selected from N, O, and S; the subscripts m and n are each independently 0 or 1 ;
  • R 1 is selected from the group consisting of Ci- 6 alkyl, halo, Ci- 6 haloalkyl, -X'-O-C M alkyl, Ci-6 haloalkoxy, -X'-cyano.
  • -C(0)OR a , -NR a C(0)R b , -X 1 -C(0)NR a R b , -X'-OH, C 3 - 6 cycloalkyl, -X'-O- C3-6 cycloalkyl, Ci- 6 hydroxyalkynyl, -X 1 -NR a R b , -X 1 - S(0) 2 R a ,-X 1 -S(0) 2 NR a R b , and X'-X ⁇ -OR 3 ;
  • R 2 is selected from the group consisting of Ci- 6 alkyl, halo, Ci- 6 haloalkyl, Ci- 6 haloalkoxy, and
  • each X 1 is independently selected from a bond and CM alkylene
  • X la is 3- to 6- membered heterocycloalkylene having 1 to 4 heteroatoms as ring vertices independently selected from N, O, and S and R a and R b are independently selected from the group consisting of hydrogen, Ci- 6 alkyl, and Ci-6 haloalkyl; and
  • Ar 1 is selected form the group consisting of phenyl and a 5- to 10- membered heteroaryl ring having 1 to 4 heteroatoms independently selected from N, O, and S, wherein Ar 1 is substituted with 0 to 4 R la substituents; each R la is independently selected from Ci- 6 alkyl, halo, Ci- 6 haloalkyl, -X 2 -0-C I-6 alkyl,
  • Ci - 6 alkyl, or C2-6 alkynyl wherein each R 3 member of (i) through (v) is substituted with 0 to 4 R 3a substituents, each of which is independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halo, Ci-6 haloalkyl, Ci- 6 haloalkoxy, -X 3 -0-Ci- 6 alkyl, -X 3 -OH, -NR e R f ,
  • R 3 member (vii) is substituted with from 0 to 3 R 3b substituents selected from the group consisting of halo, Ci-6 haloalkoxy, -O-Ci-6 alkyl, cyano, -OH, -NR e R f , and oxo, wherein each X 3 is independently selected from a bond and C1-4 alkylene, and each R e and R f is independently selected from H and Ci- 6 alkyl; or a pharmaceutically acceptable salt thereof.
  • ring A is selected from the group consisting of phenyl and a 5- to 10- membered heteroaryl ring having 1 to 4 heteroatoms independently selected from N, O, and S; the subscripts m and n are each independently 0 or 1 ;
  • R 1 is selected from the group consisting of Ci- 6 alkyl, halo, Ci- 6 haloalkyl, -X'-O-Ci ⁇ alkyl, Ci- 6 haloalkoxy, -X'-cyano.
  • -C(0)OR a , -NR a C(0)R b , -X 1 -C(0)NR a R b , -X'-OH, C3-6 cycloalkyl, Ci- 6 hydroxyalkynyl, -X 1 -NR a R b , -X 1 -S(0) 2 R a , and -X 1 -S(0) 2 NR a R b ;
  • R 2 is selected from the group consisting of Ci-6 alkyl, halo, Ci-6 haloalkyl, Ci-6 haloalkoxy, and -X'-cyano. wherein each X 1 is independently selected from a bond and C1-4 alkylene, and R a and R b are independently selected from the group consisting of hydrogen, Ci- 6 alkyl, and Ci-6 haloalkyl; and
  • Ar 1 is selected form the group consisting of phenyl and a 5- to 10- membered heteroaryl ring having 1 to 4 heteroatoms independently selected from N, O, and S, wherein Ar 1 is substituted with 0 to 4 R la substituents; each R la is independently selected from Ci- 6 alkyl, halo, Ci- 6 haloalkyl, -X 2 -0-C I-6 alkyl,
  • Ci - 6 alkyl, or C2-6 alkynyl wherein each R 3 member of (i) through (v) is substituted with 0 to 4 R 3a substituents, each of which is independently selected from Ci- 6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halo, Ci- 6 haloalkyl, Ci- 6 haloalkoxy, -X 3 -0-Ci- 6 alkyl, -X 3 -OH, -NR e R f , -NR e C(0)R f , -X 3 -NR e R f , - X 3 -cyano, and oxo; and
  • R 3 member (vii) is substituted with from 0 to 3 R 3b substituents selected from the group consisting of halo, Ci-6 haloalkoxy, -O-Ci-6 alkyl, cyano, -OH, -NR e R f , and oxo, wherein each X 3 is independently selected from a bond and C alkylene, and each R e and R f is independently selected from H and Ci-6 alkyl; or a pharmaceutically acceptable salt thereof.
  • ring A in Formula (I) is phenyl, pyridinyl, pyridazinyl, imidazolyl, pyrazolyl, triazolyl, imidazo[l,2-a]pyridinyl, [l,2,3]triazolo[l,5-a]pyridinyl, imidazo[l,5- a]pyridinyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[3,2-b]pyridinyl, pyrazolo[l,5-a]pyridinyl, [l,2,4]triazolo[l,5-a]pyridinyl, 1,6-naphthyridinyl, or 1,7-naphthyridinyl.
  • ring A in Formula (I) is a nine or ten membered heteroaryl ring. In some embodiments, ring A in Formula (I) is a nine membered heteroaryl ring. In some embodiments, ring A in Formula (I) is a ten membered heteroaryl ring.
  • ring A in Formula (I) is imidazo[l,2-a]pyridinyl, [l,2,3]triazolo[l,5- a]pyridinyl, imidazo[l,5-a]pyridinyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[3,2-b]pyridinyl, pyrazolo[l,5-a]pyridinyl, [l,2,4]triazolo[l,5-a]pyridinyl, 1,6-naphthyridinyl, or 1,7- naphthyridinyl.
  • ring A in Formula (I) is a five or six membered heteroaryl ring. In some embodiments, ring A in Formula (I) is a five membered heteroaryl ring. In some embodiments, ring A in Formula (I) is a six membered heteroaryl ring.
  • ring A in Formula (I) is pyridinyl, pyridazinyl, pyrimidinyl, imidazolyl, pyrazolyl, ortriazolyl.
  • ring A together with Ar 1 , R 1 , and R 2 in Formula (I) is selected from the group consisting of:
  • ring A together with Ar 1 , R 1 , and R 2 in Formula (I) is selected from the group consisting of:
  • ring A together with Ar 1 , R 1 , and R 2 in Formula (I) is selected from the group consisting of: In some embodiments, ring A together with Ar 1 , R 1 , and R 2 in Formula (I) is selected from the group consisting of:
  • ring A together with Ar 1 and R 1 in Formula (I) is: In some embodiments, ring A together with Ar 1 in Formula (I) is:
  • ring A together with Ar 1 in Formula (I) is:
  • ring A together with Ar 1 in Formula (I) is:
  • ring A together with Ar 1 in Formula (I) is:
  • ring A in Formula (I) is not pyrimidine.
  • ring A in Formula (I) is selected from the group consisting of phenyl, pyridinyl, pyrimidinyl, and imidazo[l,2-a]pyridinyl, 1,2,3-triazole, pyrazolyl, isoxazolyl, imidazo [1,5 -a]pyridinyl
  • ring A in Formula (I) is selected from the group consisting of phenyl, pyridinyl, pyrimidinyl, and imidazo[l,2-a]pyridinyl.
  • ring A in Formula (I) is phenyl
  • ring A in Formula (I) is pyridinyl.
  • Ar 1 is attached to ring A in the ortho position relative to the amide substituent.
  • ring A when ring A is pyridyl, the N atom of pyridyl is oxidized to form the N-oxide.
  • n in Formula (I) and subembodiments thereof is 1. In some embodiments, n in Formula (I) and subembodiments thereof is 0.
  • n is 1 in Formula (I) and subembodiments thereof n is 1 and R 1 is a 4- to 6-member heterocycloalkyl having 1 to 4 heteroatoms as ring vertices independently selected from N, O, and S. In some embodiments, n is 1 in Formula (I) and subembodiments thereof n is 1 and R 1 is a 6-membered heterocycloalkyl having 1 to 4 heteroatoms as ring vertices independently selected from N, O, and S.
  • n is 1 in Formula (I) and subembodiments thereof n is 1 and R 1 is a 5-membered heterocycloalkyl having 1 to 4 heteroatoms as ring vertices independently selected from N, O, and S. In some embodiments, n is 1 in Formula (I) and subembodiments thereof n is 1 and R 1 is a 4-membered heterocycloalkyl having 1 to 4 heteroatoms as ring vertices independently selected from N,
  • n is 1 in Formula (I) and subembodiments thereof n is 1 and R 1 is selected from the group consisting of azetinidinyl, pyrrolidinyl, pyrazolidinyl, piperidinyl, and piperazinyl. In some embodiments, n is 1 in Formula (I) and subembodiments thereof n is 1 and R 1 is azetinidinyl.
  • n is 1 in Formula (I) and subembodiments thereof and R 1 is selected from the group consisting of Ci- 6 alkyl, halo, Ci- 6 haloalkyl, -X'-O-Ci-r, alkyl, Ci- 6 haloalkoxy, -X'-cyano. -X'-OH. C3-6 cycloalkyl, and -X 1 -NR a R b .
  • n is 1 in Formula (I) and subembodiments thereof and R 1 is selected from the group consisting of Ci- 6 alkyl, halo, -X'-cyano. and Ci- 6 haloalkyl.
  • n is 1 in Formula (I) and subembodiments thereof and R 1 is selected from the group consisting of-X'-0-Ci- 6 alkyl, Ci- 6 haloalkoxy, -X'-OH. and -X 1 -NR a R b .
  • n is 1 in Formula (I) and subembodiments thereof and R 1 is selected from the group consisting of-X'-O- C3-6 cycloalkyl, and X'-X' DR 3 .
  • n is 1 in Formula (I) and subembodiments thereof and R 1 is selected from the group consisting of C 1-6 alkyl, halo, - X'-cyano, and Ci-6 haloalkyl, -X'-O- C3-6 cycloalkyl, and X'-X' a -OR a .
  • R 1 is selected from the group consisting of Ci-6 alkyl, halo, -X'-cyano. and Ci-6 haloalkyl, and -X'-O- C3-6 cycloalkyl.
  • n is 1 in Formula (I) and subembodiments thereof and R 1 is selected from the group consisting of Ci- 6 alkyl and -X'-OH.
  • n is 1 in Formula (I) and subembodiments thereof and R 1 is selected from the group consisting of methyl and hydroxymethyl. In some embodiments, n is 1 in Formula (I) and subembodiments thereof and R 1 is selected from the group consisting of ethyl and hydroxy ethyl.
  • n is 1 in Formula (I) and subembodiments thereof and R 1 is methyl. In some embodiments, n is 1 in Formula (I) and subembodiments thereof and R 1 is ethyl or propyl. In some embodiments, n is 1 in Formula (I) and subembodiments thereof and R 1 is O-cyclopropyl. In some embodiments, n is 1 in Formula (I) and subembodiments thereof and R 1 is O-cyclopropyl. In some embodiments, n is 1 in Formula (I) and subembodiments thereof and R 1 is -CFh-O-cyclopropyl.
  • m is 1 in Formula (I) and R 2 is Ci- 6 alkyl, halo, Ci- 6 haloalkyl, and Ci- 6 haloalkoxy. In some embodiments, m is 1 in Formula (I) and R 2 is Ci-6 alkyl, halo, and Ci-6 haloalkyl.
  • n in Formula (I) and subembodiments thereof is 0. In some embodiments, m in Formula (I) and subembodiments thereof is 1.
  • each X 1 in Formula (I) and subembodiments thereof is a bond. In some embodiments, each X 1 in Formula (I) and subembodiments thereof is CM alkylene. In some embodiments, each X 1 in Formula (I) and subembodiments thereof is C1-2 alkylene. In some embodiments, each X 1 in Formula (I) and subembodiments thereof is methylene.
  • each R a and R b in Formula (I) and subembodiments thereof is hydrogen. In some embodiments, each R a is hydrogen and each R b in Formula (I) and subembodiments thereof is CM alkyl or CM haloalkyl. In some embodiments, each R a and R b in Formula (I) and subembodiments thereof is CM alkyl. In some embodiments, each R a and R b in Formula (I) and subembodiments thereof is C1-2 alkyl. In some embodiments, each R a and R b in Formula (I) and subembodiments thereof is methyl.
  • each R a and R b in Formula (I) and subembodiments thereof is CM haloalkyl. In some embodiments, each R a and R b in Formula (I) and subembodiments thereof is C1-2 haloalkyl.
  • the compound has the Formula (Iaa): or a pharmaceutically acceptable salt thereof, wherein Z 1 and Z 2 are ring vertices of ring A linked by a single or a double bond, and each of Z 1 and Z 2 are carbon atoms.
  • the compound has the Formula (la): or a pharmaceutically acceptable salt thereof. In some embodiments, the compound has the Formula (lb): or a pharmaceutically acceptable salt thereof.
  • the compound has the Formula (Ic): or a pharmaceutically acceptable salt thereof.
  • Ar 1 in Formula (I), (la), (lb), and (Ic) is selected from the group consisting of phenyl, pyridinyl, benzopyrazolyl, benzimidazolyl, imidazolyl, pyridazyl, imidazo[l,2-a]pyrimidinyl, oxazolo[4,5-b]pyridinyl, oxazolo[5,4-b]pyridinyl, thiazolo[4,5- b]pyridinyl, benzo[d]thiazole, indazolyl, [l,2,4]triazolo[l,5-a]pyrimidinyl, [l,2,4]triazolo[l,5-b]pyridazinyl, and tetrazolo[l,5-a]pyridinyl, each of which is substituted with 0 to 4 R la
  • Ar 1 in Formula (I), (la), (lb), and (Ic) is selected from the group consisting of phenyl, pyridinyl, benzopyrazolyl, benzimidazolyl, imidazolyl, and pyridazyl each of which is substituted with 0 to 4 R la .
  • Ar 1 in Formula (I), (la), (lb), and (Ic) is selected from the group consisting of 3H-imidazo[4,5-b]pyridinyl, imidazo[l,2-a]pyrimidinyl, oxazolo[4,5- b]pyridinyl, oxazolo[5,4-b]pyridinyl, thiazolo[4,5-b]pyridinyl, benzo[d]thiazole, benzo[c]isothiazolyl, indazolyl, [l,2,4]triazolo[l,5-a]pyrimidinyl, [l,2,4]triazolo[l,5- b]pyridazinyl, tetrazolo[l,5-a]pyridinyl, and [l,2,4]triazolo[l,5-a]pyridinyl, each of which is substituted with 0 to 4 R la .
  • Ar 1 in Formula (I), (la), (lb), and (Ic) is phenyl substituted with 0 to 4
  • Ar 1 in Formula (I), (la), (lb), and (Ic) is
  • Ar 1 in Formula (I), (la), (lb), and (Ic) is pyridinyl substituted with 0 to 4 R la .
  • Ar 1 in Formula (I), (la), (lb), and (Ic) is naphthyl substituted with 0 to 4 R la .
  • Ar 1 in Formula (I), (la), (lb), and (Ic) is pyridin-2-one substituted with 0 to 4 R la .
  • Ar 1 in Formula (I), (la), (lb), and (Ic) is naphthyl substituted with 0 to 4 R la . In some embodiments, Ar 1 in Formula (I), (la), (lb), and (Ic) is pyridin-2-one substituted with 0 to 4 R la .
  • Ar 1 in Formula (I), (la), (lb), and (Ic) is substituted with 0 to 3 R la .
  • Ar 1 in Formula (I), (la), (lb), and (Ic) is substituted with 0 to 2 R la .
  • the compound has the Formula (lal): (lal), or a pharmaceutically acceptable salt thereof.
  • the compound has the Formula (lb 1): or a pharmaceutically acceptable salt thereof. In some embodiments, the compound has the Formula (Icl): or a pharmaceutically acceptable salt thereof.
  • the compound has the Formula (Ia2): or a pharmaceutically acceptable salt thereof.
  • the compound has the Formula (Ib2): or a pharmaceutically acceptable salt thereof.
  • the compound has the Formula (Ic2): or a pharmaceutically acceptable salt thereof.
  • each R la in Formula (I) and subembodiments thereof is independently selected from Ci-6 alkyl, halo, Ci-6 haloalkyl, -X 2 -0-CI-6 alkyl, Ci-6 haloalkoxy, C3-6 cycloalkyl, -NR a R b , -X 2 -cyano, and -X 2 -OH.
  • each R la in Formula (I) and subembodiments thereof is independently selected from Ci- 6 alkyl, halo, Ci- 6 haloalkyl, - X 2 -0-C I-6 alkyl, Ci- 6 haloalkoxy, C3-6 cycloalkyl, -NR a R b , -X 2 -cyano, -X 2 -OH, and -X 2 - S(0)R c .
  • each R la in Formula (I) and subembodiments thereof is independently selected from Ci- 6 alkyl, halo, Ci- 6 haloalkyl, -O-Ci- 6 alkyl, Ci- 6 haloalkoxy, C3-6 cycloalkyl, -NR a R b , and -X 2 -OH.
  • each R la in Formula (I) and subembodiments thereof is independently selected from Ci- 6 alkyl, halo, Ci- 6 haloalkyl, -X 2 -0-C I-6 alkyl, Ci- 6 haloalkoxy, C3-6 cycloalkyl, -NR a R b , -X 2 -cyano, -X 2 -OH, and -S(0)R c .
  • each R la in Formula (I) and subembodiments thereof is independently selected from methyl, ethyl, fluoro, chloro, bromo, trifluoromethyl, difluoromethyl, methoxy, ethoxy, difluoromethoxy, cyclopropyl, -NH2, hydroxymethyl, and 1 -hydroxy ethyl.
  • each R la in Formula (I) and subembodiments thereof is independently selected from methyl, ethyl, fluoro, chloro, bromo, trifluoromethyl, difluoromethyl, methoxy, ethoxy, and difluoromethoxy.
  • each R la in Formula (I) and subembodiments thereof is independently selected from ethyl, fluoro, chloro, difluoromethyl, and ethoxy. In some embodiments, each R la in Formula (I) and subembodiments thereof is independently selected from methyl, fluoro, chloro, trifluoromethyl, difluoromethyl, methoxy, and difluoromethoxy. In some embodiments, each R la in Formula (I) and subembodiments thereof is independently selected methyl, ethyl, fluoro, cyclopropyl, -NH 2 , hydroxymethyl, and 1 -hydroxy ethyl.
  • each R la in Formula (I) and subembodiments thereof is independently selected from Ci-6 alkyl, halo, -O-Ci-6 alkyl, -C(0)2R C , -C1-4 alkoxy-Ci alkoxy, -X 2 - C(0)NR c R d , -X 2 -S(0) 2 NR c R d , -0-X 2 -cyano, -X 2 -S(0) 2 R c , and -X 2 -N(R d )S(0) 2 R c .
  • each R la in Formula (I) and subembodiments thereof is independently selected from -C(0) 2 R c , -CM alkoxy-Ci- 4 alkoxy, -X 2 -C(0)NR c R d , -X 2 -S(0) 2 NR c R d , -O- X 2 -cyano, -X 2 -S(0) 2 R c , and -X 2 -N(R d )S(0) 2 R c .
  • each R la in Formula (I) and subembodiments thereof wherein at least one R la is Y and Y is selected from phenyl, benzyl, 4- to 6-membered heterocycloalkyl, and 5- or 6-membered heteroaryl, wherein each heterocycloalkyl and heteroaryl has 1 or 2 ring members independently selected from O, N and S; and each Y is substituted with 0, 1 or 2 groups independently selected from halo, oxo, Ci-4 alkyl, Ci-4 alkoxy, and Ci-4 haloalkyl.
  • each R la in Formula (I) and subembodiments thereof wherein at least one R la is Y and Y is 4- to 6-membered heterocycloalkyl or 5- or 6-membered heteroaryl, wherein each heterocycloalkyl and heteroaryl has 1 or 2 ring members independently selected from O, N and S; and each Y is substituted with 0, 1 or 2 groups independently selected from halo, oxo, Ci-4 alkyl, Ci-4 alkoxy, and Ci-4 haloalkyl.
  • the 4- to 6-membered heterocycloalkyl is selected from the group consisting of piperidinyl, morpholinyl, andtetrahydropyranyl.
  • each R la in Formula (I) and subembodiments thereof wherein at least one R la is Y and Y is 5- or 6-membered heteroaryl, wherein each heteroaryl has 1 or 2 ring members independently selected from O, N and S; and each Y is substituted with 0, 1 or 2 groups independently selected from halo, oxo, Ci- 4 alkyl, Ci- 4 alkoxy, and Ci- 4 haloalkyl.
  • the 5- to 6- membered heteroaryl is pyrazolyl.
  • two R la groups, in Formula (I) and subembodiments thereof, on adjacent ring vertices combine to form a 4 to 6 membered heterocycloalkyl having 1 to 2 heteroatoms as ring vertices independently selected from N, O, and S.
  • two R la groups, in Formula (I) and subembodiments thereof, on adjacent ring vertices combine to form a 5 membered heterocycloalkyl having 1 to 2 heteroatoms as ring vertices independently selected from N, O, and S.
  • the heterocycloalkyl ring has 1 or 2 double bonds between ring members.
  • the heterocycloalkyl ring is substituted with 0 to 4 groups independently selected from oxo, halo, C alkyl, C M alkoxy, and CM haloalkyl.
  • two R la groups, in Formula (I) and subembodiments thereof, on adjacent ring vertices combine to form a 4 to 6 membered cycloalkyl.
  • the cycloalkyl ring has 1 or 2 double bonds between ring members.
  • the cycloalkyl ring is substituted with 0 to 4 groups independently selected from oxo, halo, CM alkyl, CM alkoxy, and CM haloalkyl.
  • each R la in Formula (I) and subembodiments thereof is independently selected from methyl, fluoro, chloro, trifluoromethyl, difluoromethyl, methoxy, ethoxy, difluoromethoxy, and cyclopropyl.
  • each X 2 in Formula (I) and subembodiments thereof is a bond. In some embodiments, each X 2 in Formula (I) and subembodiments thereof is C M alkylene. In some embodiments, each X 2 in Formula (I) and subembodiments thereof is C1-2 alkylene. In some embodiments, each X 2 in Formula (I) and subembodiments thereof is methylene.
  • each R c and R d in Formula (I) and subembodiments thereof is hydrogen, C M alkyl, C3-5 cycloalkyl and Ci- 6 haloalkyl. In some embodiments, each R c and R d in Formula (I) and subembodiments thereof is hydrogen, Ci- 6 alkyl, and Ci- 6 haloalkyl. In some embodiments, each R c and R d in Formula (I) and subembodiments thereof is hydrogen. In some embodiments, each R c is hydrogen and each R d in Formula (I) and subembodiments thereof is CM alkyl or CM haloalkyl.
  • each R c and R d in Formula (I) and subembodiments thereof is CM alkyl. In some embodiments, each R c and R d in Formula (I) and subembodiments thereof is C1-2 alkyl. In some embodiments, each R c and R d in Formula (I) and subembodiments thereof is methyl. In some embodiments, each R c and R d in Formula (I) and subembodiments thereof is CM haloalkyl. In some embodiments, each R c and R d in Formula (I) and subembodiments thereof is C1-2 haloalkyl.
  • R 3 in Formula (I) and subembodiments thereof is C6-12 spirocyclyl or C3-6 cycloalkyl, each of which is substituted with 0 to 4 R 3a .
  • R 3 in Formula (I) and subembodiments thereof is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl , and is substituted with 0 to 4 R 3a .
  • R 3 in Formula (I) and subembodiments thereof is selected from the group consisting of spiro [3.3] heptane, spiro[4.4]nonane, spiro[3.4]octane.
  • R 3 in Formula (I) and subembodiments thereof is Ce-i i bridged cycloalkyl, each of which is substituted with 0 to 4 R 3a .
  • the Ce-n bridged cycloalkyl has the structure each of which is substituted with 0 to 4 R 3a .
  • R 3 is a 3- to 6-membered heterocycloalkyl having 1 to 4 heteroatoms as ring vertices independently selected from N, O, and S, and is substituted with 0 to 4 R 3a .
  • R 3 in Formula (I) and subembodiments thereof is a 5 - membered heterocycloalkyl substituted with 0 to 4 R 3a . In some embodiments, R 3 in Formula (I) and subembodiments thereof is a 6- membered heterocycloalkyl substituted with 0 to 4 R 3a .
  • R 3 in Formula (I) and subembodiments thereof is selected from the group consisting of piperidinyl, piperazinyl, morpholinyl, 2-oxopiperazinyl, 2- tetrahydropyranyl, 3,6-dihydro-2H-pyranyl, 2-oxo-l,2-dihydropyridinyl, thiomorpholinyl, and 1,1- dioxothiomorpholinyl each of which is substituted with 0 to 4 R 3a
  • R 3 in Formula (I) and subembodiments thereof is selected from the group consisting of tetrahydropyran, oxetanyl, tetrahydrofuranyl, and tetrahydrothiopyranyl, each of which is substituted with 0 to 4 R 3a .
  • R 3 in Formula (I) and subembodiments thereof is tetrahydrothiopyranyl substituted with 2
  • R 3 in Formula (I) and subembodiments thereof is a 6- to 10-membered bicyclic heterocyclyl having 1 to 4 heteroatoms as ring vertices independently selected from N, O, and S, and is substituted with 0 to 4 R 3a .
  • R 3 in Formula (I) and subembodiments thereof is selected from the group consisting of 6-oxohexahydropyrrolo[l,2- a]pyrazin-2(lH)-yl and 2,3-dihydro-4H-benzo[b][l,4]oxazin-4-yl and is substituted with 0 to 4 R 3a .
  • R 3 in Formula (I) and subembodiments thereof is selected from the group consisting of 6-oxohexahydropyrrolo[l,2-a]pyrazin-2(lH)-yl, 3-oxo-3,4-dihydro- 2H-benzo[b][l,4]oxazin-8-yl, benzo[d][l,3]dioxol-4-yl, (3,4-dihydro-2H-l,4-benzoxazin-8- yl), [5H,6H,7H-pyrazolo[l,5-a]pyrimidin-4-yl] and 2,3-dihydro-4H-benzo[b][l,4]oxazin-4- yl, and is substituted with 0 to 4 R 3a .
  • R 3 in Formula (I) and subembodiments thereof is a 6- to 10-membered bridged heterocyclyl having 1 to 4 heteroatoms as ring vertices independently selected from N, O, and S, and is substituted with 0 to 4 R 3a .
  • R 3 in Formula (I) and subembodiments thereof is selected from the group consisting of 2-azabicyclo[2.2.2]octane, quinuclidine, and 7-oxabicyclo[2.2.1]heptane, and is substituted with 0 to 4 R 3a .
  • R 3 in Formula (I) and subembodiments thereof is a 6- to 12-membered spiroheterocyclyl having 1 to 4 heteroatoms as ring vertices independently selected from N,
  • R 3 in Formula (I) and subembodiments thereof is selected from the group consisting of 4-oxaspiro[2.4]heptane, 2,6- diazaspiro[3.3]heptane, 2,6-diazaspiro[3.4]octane, 2-azaspiro[3.4]octane, 2-azaspiro
  • R 3 in Formula (I) and subembodiments thereof is substituted with 0 to 2 R 3a . In some embodiments, R 3 in Formula (I) and subembodiments thereof is substituted with 1 R 3a . In some embodiments, R 3 in Formula (I) and subembodiments thereof is substituted with 2 R 3a .
  • each R 3a in Formula (I) and subembodiments thereof is selected from the group consisting of Ci-6 alkyl, halo, -X 3 -0-CI-6 alkyl, Ci-6 haloalkyl, Ci- 6 haloalkoxy, -X 3 -OH, -ONO2, 4- to 6-member heterocycloalkyl having 1 to 4 heteroatoms as ring vertices independently selected from N, O, and S and oxo.
  • each R 3a in Formula (I) and subembodiments thereof is selected from the group consisting of Ci-6 alkyl, halo, -X 3 -0-CI-6 alkyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, -X 3 -OH, and oxo.
  • each R 3a in Formula (I) and subembodiments thereof is selected from the group consisting of Ci- 6 alkyl, halo, -X 3 -OH, and oxo.
  • each R 3a in Formula (I) and subembodiments thereof is selected from the group consisting of methyl, -OH, and oxo.
  • at least one R 3a in Formula (I) and subembodiments thereof is selected from the group consisting of a 4- to 6-member heterocycloalkyl having 1 to 4 heteroatoms as ring vertices independently selected from N,
  • At least one R 3a in Formula (I) and subembodiments thereof is selected from the group consisting of tetrahydropyranyl and oxetanyl.
  • R 3 is in Formula (I) and subembodiments thereof hydrogen.
  • R 3 is in Formula (I) and subembodiments thereof Ci- 6 alkyl or C2-6 alkynyl, and is substituted with 0 to 4 R 3b .
  • R 3 in Formula (I) and subembodiments thereof is selected from the group consisting of 2-propynyl, ethyl, methyl, 2,2,-dimethylpropyl, isobutyl, isopropyl, and n-propyl, and is substituted with 0 to 4 R 3b .
  • R 3 in Formula (I) and subembodiments thereof is methyl and is substituted with 0 to 3 R 3b .
  • R 3 in Formula (I) and subembodiments thereof is methyl.
  • R 3 in Formula (I) and subembodiments thereof is Ci- 6 alkyl or C2-6 alkynyl and is substituted with 0 to 3 R 3b . In some embodiments, R 3 in Formula (I) and subembodiments thereof is Ci- 6 alkyl or C2-6 alkynyl and is substituted with 0 to 2 R 3b . In some embodiments, R 3 in Formula (I) and subembodiments thereof is Ci- 6 alkyl or C2-6 alkynyl and is substituted with 1 R 3b .
  • each R 3b in Formula (I) and subembodiments thereof is selected from the group consisting of halo, C1-3 haloalkyl, -O-Ci-6 alkyl, cyano,-OH, and -CONR e R f .
  • each R 3b in Formula (I) and subembodiments thereof is selected from the group consisting of halo, -O-Ci-6 alkyl, cyano, and -OH.
  • each R 3b in Formula (I) and subembodiments thereof is selected from the group consisting of fluoro, methoxy, cyano, and -OH.
  • each R 3b in Formula (I) and subembodiments thereof is selected from the group consisting of-O-Ci- 6 alkyl, cyano, and - OH. In some embodiments, each R 3b in Formula (I) and subembodiments thereof is selected from the group consisting of methoxy, cyano, and -OH.
  • each X 3 in Formula (I) and subembodiments thereof is a bond. In some embodiments, each X 3 in Formula (I) and subembodiments thereof is CM alkylene. In some embodiments, each X 3 in Formula (I) and subembodiments thereof is C1- 2 alkylene. In some embodiments, each X 3 in Formula (I) and subembodiments thereof is methylene.
  • each R e and R f in Formula (I) and subembodiments thereof is hydrogen. In some embodiments, each R e is hydrogen and each R f in Formula (I) and subembodiments thereof is CM alkyl or CM haloalkyl. In some embodiments, each R e and R f in Formula (I) and subembodiments thereof is CM alkyl. In some embodiments, each R e and R f in Formula (I) and subembodiments thereof is C1-2 alkyl. In some embodiments, each R e and R f in Formula (I) and subembodiments thereof is methyl.
  • each R e and R f in Formula (I) and subembodiments thereof is CM haloalkyl. In some embodiments, each R e and R f in Formula (I) and subembodiments thereof is C1-2 haloalkyl.
  • the compounds or pharmaceutically acceptable salts thereof is a compound from Table 1, Table 2 or the Examples.
  • the compounds or pharmaceutically acceptable salts thereof is a compound from Table 1, Table 2, Table 3, or the Examples.
  • the compounds or pharmaceutically acceptable salts thereof is a compound from Table 1, Table 2, or Table 3.
  • the compounds or pharmaceutically acceptable salts thereof is a compound from Table 1 or Table 2. In some embodiments, the compounds or pharmaceutically acceptable salts thereof is a compound from Table 1.
  • the compounds or pharmaceutically acceptable salts thereof is a compound from Table 2.
  • the compounds or pharmaceutically acceptable salts thereof is a compound from Table 3.
  • the compounds or pharmaceutically acceptable salts thereof is a compound selected from examples 86, 87, 89, 90, 96, 97, 106, 108, 111, and 113.
  • the compounds or pharmaceutically acceptable salts thereof is a compound selected from examples 79 to 85, 88, 91 to 93, 100 to 105, 109, 112, 114 to 119, 122, 124 to 143, and 145 to 233.
  • the compounds disclosed herein can be prepared as described in the examples section, below. For those compounds without detailed synthetic write-ups, it is understood that these compounds can be prepared following the general procedures described herein.
  • compositions suitable for administration to a subject may be in the form of compositions suitable for administration to a subject.
  • compositions are pharmaceutical compositions comprising a compound of Formula (I) or a subembodiment or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients.
  • the compound of Formula (I) or a subembodiment or a pharmaceutically acceptable salt thereof is present in a therapeutically effective amount.
  • the pharmaceutical compositions may be used in all the methods disclosed herein; thus, for example, the pharmaceutical compositions can be administered ex vivo or in vivo to a subject in order to practice the therapeutic methods and uses described herein.
  • compositions can be formulated to be compatible with the intended method or route of administration; exemplary routes of administration are set forth herein. Furthermore, the pharmaceutical compositions may be used in combination with other therapeutically active agents or compounds as described herein in order to treat the diseases, disorders and conditions contemplated by the present disclosure.
  • compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, capsules, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups, solutions, microbeads or elixirs.
  • Tablets, capsules and the like contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets, capsules, and the like.
  • excipients can include diluents, granulating agents, disintegrating agents, binding agents, and lubricating agents.
  • the tablets, capsules and the like suitable for oral administration may be uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action.
  • Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium.
  • Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture thereof. Such excipients can include suspending agents, dispersing agents and wetting agents.
  • excipients can include suspending agents, dispersing agents and wetting agents.
  • the aqueous suspensions may also contain one or more preservatives.
  • Oily suspensions may be formulated by suspending the active ingredient in an oil. Suitable oils are known in the art.
  • the oily suspensions may contain additional agents such as a thickening agent or a sweetening agent.
  • Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.
  • a dispersing or wetting agent e.g., kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, ka
  • compositions may also be in the form of oil-in-water emulsions.
  • Suitable emulsifying agents are known in the art.
  • compositions typically comprise a therapeutically effective amount of a compound of Formula (I) or a subembodiment or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipient.
  • suitable pharmaceutically acceptable excipients include, but are not limited to, antioxidants, preservatives, emulsifying agents, suspending agents, dispersing agents, solvents, fillers, bulking agents, detergents, buffers, vehicles, diluents, and/or adjuvants.
  • Depot injections which are generally administered subcutaneously or intramuscularly, may also be utilized to release the compound of Formula (I) or a subembodiment or a pharmaceutically acceptable salt thereof disclosed herein over a defined period of time.
  • Depot injections are usually either solid- or oil-based and generally comprise at least one of the formulation components set forth herein.
  • One of ordinary skill in the art is familiar with possible formulations and uses of depot injections.
  • the pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension.
  • the suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents mentioned herein.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non toxic parenterally acceptable diluent or solvent, which are known in the art.
  • a compound of Formula (I) or a subembodiment or a pharmaceutically acceptable salt thereof may also be administered in the form of suppositories for rectal administration or sprays for nasal or inhalation use.
  • the suppositories can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are known in the art.
  • All the compounds and pharmaceutical compositions provided herein can be used in all the methods provided herein.
  • the compounds and pharmaceutical compositions provided herein can be used in all the methods for treatment and/or prevention of all diseases or disorders provided herein.
  • the compounds and pharmaceutical compositions provided herein are for use as a medicament.
  • Suitable routes of administration include oral, parenteral (e.g., intramuscular, intravenous, subcutaneous (e.g., injection or implant), intraperitoneal, intracistemal, intraarticular, intraperitoneal, intracerebral (intraparenchymal) and intracerebro ventricular), nasal, vaginal, sublingual, intraocular, rectal, topical (e.g., transdermal), buccal and inhalation.
  • parenteral e.g., intramuscular, intravenous, subcutaneous (e.g., injection or implant), intraperitoneal, intracistemal, intraarticular, intraperitoneal, intracerebral (intraparenchymal) and intracerebro ventricular
  • nasal, vaginal, sublingual, intraocular, rectal topical (e.g., transdermal), buccal and inhalation.
  • Depot injections which are generally administered subcutaneously or intramuscularly, may also be utilized to administer the compounds of Formula (I) or a subembodiment or a pharmaceutically acceptable salt thereof over a defined period of time.
  • Particular embodiments of the present invention contemplate oral administration.
  • Combination Therapy contemplates the use of compounds of Formula (I) or a subembodiment or a pharmaceutically acceptable salt thereof in combination with one or more active therapeutic agents (e.g., chemotherapeutic agents) or other prophylactic or therapeutic modalities (e.g., radiation).
  • active therapeutic agents e.g., chemotherapeutic agents
  • prophylactic or therapeutic modalities e.g., radiation
  • the various active agents frequently have different, complementary mechanisms of action.
  • Such combination therapy may be especially advantageous by allowing a dose reduction of one or more of the agents, thereby reducing or eliminating the adverse effects associated with one or more of the agents.
  • such combination therapy may have a synergistic therapeutic or prophylactic effect on the underlying disease, disorder, or condition.
  • “combination” is meant to include therapies that can be administered separately, for example, formulated separately for separate administration (e.g., as may be provided in a kit), and therapies that can be administered together in a single formulation (i.e., a “co-formulation”).
  • the compounds of Formula (I) or a subembodiment or a pharmaceutically acceptable salt thereof are administered or applied sequentially, e.g., where one agent is administered prior to one or more other agents.
  • the compounds of Formula (I) or a subembodiment or a pharmaceutically acceptable salt thereof are administered simultaneously, e.g., where two or more agents are administered at or about the same time; the two or more agents may be present in two or more separate formulations or combined into a single formulation (i.e., a co -formulation). Regardless of whether the two or more agents are administered sequentially or simultaneously, they are considered to be administered in combination for purposes of the present disclosure.
  • the compounds of Formula (I) or a subembodiment or a pharmaceutically acceptable salt thereof may be used in combination with at least one other (active) agent in any manner appropriate under the circumstances.
  • treatment with the at least one active agent and at least one compound of Formula (I) or a subembodiment or a pharmaceutically acceptable salt thereof is maintained over a period of time.
  • treatment with the at least one active agent is reduced or discontinued (e.g., when the subject is stable), while treatment with the compound of Formula (I) or a subembodiment or a pharmaceutically acceptable salt thereof is maintained at a constant dosing regimen.
  • treatment with the at least one active agent is reduced or discontinued (e.g., when the subject is stable), while treatment with a compound of Formula (I) or a subembodiment or a pharmaceutically acceptable salt thereof is reduced (e.g., lower dose, less frequent dosing or shorter treatment regimen).
  • treatment with the at least one active agent is reduced or discontinued (e.g., when the subject is stable), and treatment with the compound of Formula (I) or a subembodiment or a pharmaceutically acceptable salt thereof is increased (e.g., higher dose, more frequent dosing or longer treatment regimen).
  • treatment with the at least one active agent is maintained and treatment with the compound of Formula (I) or a subembodiment or a pharmaceutically acceptable salt thereof is reduced or discontinued (e.g., lower dose, less frequent dosing or shorter treatment regimen).
  • treatment with the at least one active agent and treatment with the compound of Formula (I) or a subembodiment or a pharmaceutically acceptable salt thereof are reduced or discontinued (e.g., lower dose, less frequent dosing or shorter treatment regimen).
  • the present disclosure provides methods for treating cancer with a compound of Formula (I) or a subembodiment or a pharmaceutically acceptable salt thereof and at least one additional therapeutic or diagnostic agent.
  • the compound of Formula (I) or a subembodiment or a pharmaceutically acceptable salt thereof is administered in combination with at least one additional therapeutic agent.
  • the additional therapeutic agent is a signal transduction inhibitor (STI) or chemotherapeutic agent.
  • the present disclosure provides methods for treating cancer comprising administration of a compound of Formula (I) or a subembodiment or a pharmaceutically acceptable salt thereof described herein in combination with a signal transduction inhibitor (STI) to achieve additive or synergistic suppression of tumor growth.
  • a signal transduction inhibitor refers to an agent that selectively inhibits one or more steps in a signaling pathway.
  • Agents involved in immunomodulation can also be used in combination with one or more compounds of Formula (I) or a subembodiment or a pharmaceutically acceptable salt thereof described herein for the suppression of tumor growth in cancer patients.
  • the present disclosure provides methods for treating cancer comprising administration of a compound of Formula (I) or a subembodiment or a pharmaceutically acceptable salt thereof described herein in combination with a chemotherapeutic agents.
  • Chemotherapeutic agents also include anti-hormonal agents that act to regulate or inhibit hormonal action on tumors such as anti-estrogens.
  • combination therapy comprises administration of a hormone or related hormonal agent.
  • the present disclosure also contemplates the use of the compounds of Formula (I) or a subembodiment or a pharmaceutically acceptable salt thereof described herein in combination with immune checkpoint inhibitors.
  • immune checkpoint inhibitors The tremendous number of genetic and epigenetic alterations that are characteristic of all cancers provides a diverse set of antigens that the immune system can use to distinguish tumor cells from their normal counterparts.
  • immune checkpoints are crucial for the prevention of autoimmunity (i.e., the maintenance of self-tolerance) and also for the protection of tissues from damage when the immune system is responding to pathogenic infection.
  • the expression of immune checkpoint proteins can be dysregulated by tumors as an important immune resistance mechanism.
  • immune checkpoint inhibitors include but are not limited to CTLA-4, PD-1, PD-L1, BTLA, TIM3, LAG3,
  • Cell-based modulators of anti-cancer immunity include but are not limited to chimeric antigen receptor T-cells, tumor infdtrating T-cells and dendritic-cells.
  • the present disclosure encompasses pharmaceutically acceptable salts, acids or derivatives of any of the above.
  • the compounds of Formula (I) or a subembodiment or a pharmaceutically acceptable salt thereof provided herein may be administered to a subject in an amount that is dependent upon, for example, the goal of administration (e.g., the degree of resolution desired); the age, weight, sex, and health and physical condition of the subject to which the formulation is being administered; the route of administration; and the nature of the disease, disorder, condition or symptom thereof.
  • the dosing regimen may also take into consideration the existence, nature, and extent of any adverse effects associated with the agent(s) being administered. Effective dosage amounts and dosage regimens can readily be determined from, for example, safety and dose-escalation trials, in vivo studies (e.g., animal models), and other methods known to the skilled artisan.
  • dosing parameters dictate that the dosage amount be less than an amount that could be irreversibly toxic to the subject (the maximum tolerated dose (MTD)) and not less than an amount required to produce a measurable effect on the subject.
  • MTD maximum tolerated dose
  • Such amounts are determined by, for example, the pharmacokinetic and pharmacodynamic parameters associated with ADME, taking into consideration the route of administration and other factors.
  • An effective dose is the dose or amount of an agent that produces a therapeutic response or desired effect in some fraction of the subjects taking it.
  • the “median effective dose” or ED50 of an agent is the dose or amount of an agent that produces a therapeutic response or desired effect in 50% of the population to which it is administered.
  • the ED50 is commonly used as a measure of reasonable expectance of an agent’s effect, it is not necessarily the dose that a clinician might deem appropriate taking into consideration all relevant factors.
  • the effective amount is more than the calculated ED50, in other situations the effective amount is less than the calculated ED50, and in still other situations the effective amount is the same as the calculated ED50.
  • an effective dose of a compound of Formula (I) or a subembodiment or a pharmaceutically acceptable salt thereof, as provided herein may be an amount that, when administered in one or more doses to a subject, produces a desired result relative to a healthy subject.
  • an effective dose may be one that improves a diagnostic parameter, measure, marker and the like of that disorder by at least about 5%, at least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or more than 90%, where 100% is defined as the diagnostic parameter, measure, marker and the like exhibited by a normal subject.
  • the compounds of Formula (I) or a subembodiment or a pharmaceutically acceptable salt thereof disclosed herein may be administered (e.g., orally) at dosage levels of about 0.01 mg/kg to about 50 mg/kg, or about 1 mg/kg to about 25 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect.
  • compositions can be provided in the form of tablets, capsules and the like containing from 1.0 to 1000 milligrams of the active ingredient, particularly 1.0, 3.0, 5.0, 10.0, 15.0, 20.0, 25.0, 50.0, 75.0, 100.0, 150.0, 200.0, 250.0, 300.0, 400.0, 500.0, 600.0, 750.0, 800.0, 900.0, and 1000.0 milligrams of the active ingredient.
  • the dosage of the compound of Formula (I) or a subembodiment or a pharmaceutically acceptable salt thereof is contained in a “unit dosage form”.
  • unit dosage form refers to physically discrete units, each unit containing a predetermined amount of the compound of Formula (I) or a subembodiment or a pharmaceutically acceptable salt thereof, either alone or in combination with one or more additional agents, sufficient to produce the desired effect. It will be appreciated that the parameters of a unit dosage form will depend on the particular agent and the effect to be achieved.
  • kits comprising a compound of Formula (I) or a subembodiment or a pharmaceutically acceptable salt thereof.
  • the kits are generally in the form of a physical structure housing various components, as described below, and may be utilized, for example, in practicing the methods described above.
  • a kit can include one or more of the compound of Formula (I) or a subembodiment or a pharmaceutically acceptable salt thereof disclosed herein (provided in, e.g., a sterile container), which may be in the form of a pharmaceutical composition suitable for administration to a subject.
  • the compound of Formula (I) or a subembodiment or a pharmaceutically acceptable salt thereof can be provided in a form that is ready for use (e.g., a tablet or capsule) or in a form requiring, for example, reconstitution or dilution (e.g., a powder) prior to administration.
  • the kit may also include diluents (e.g., sterile water), buffers, pharmaceutically acceptable excipients, and the like, packaged with or separately from the compounds of Formula (I) or a subembodiment or a pharmaceutically acceptable salt thereof.
  • diluents e.g., sterile water
  • the kit may contain the several agents separately or they may already be combined in the kit.
  • Each component of the kit may be enclosed within an individual container, and all of the various containers may be within a single package.
  • a kit of the present invention may be designed for conditions necessary to properly maintain the components housed therein (e.g., refrigeration or freezing).
  • a kit may contain a label or packaging insert including identifying information for the components therein and instructions for their use (e.g., dosing parameters, clinical pharmacology of the active ingredient(s), including mechanism of action, pharmacokinetics and pharmacodynamics, adverse effects, contraindications, etc.). Labels or inserts can include manufacturer information such as lot numbers and expiration dates.
  • the label or packaging insert may be, e.g., integrated into the physical structure housing the components, contained separately within the physical structure, or affixed to a component of the kit (e.g., an ampule, tube or vial).
  • Labels or inserts can additionally include, or be incorporated into, a computer readable medium, such as a disk (e.g., hard disk, card, memory disk), optical disk such as CD- or DVD-ROM/RAM, DVD, MP3, magnetic tape, or an electrical storage media such as RAM and ROM or hybrids of these such as magnetic/optical storage media, FLASH media or memory-type cards.
  • a computer readable medium such as a disk (e.g., hard disk, card, memory disk), optical disk such as CD- or DVD-ROM/RAM, DVD, MP3, magnetic tape, or an electrical storage media such as RAM and ROM or hybrids of these such as magnetic/optical storage media, FLASH media or memory-type cards.
  • the actual instructions are not present in the kit, but means for obtaining the instructions from a remote source, e.g., via the internet, are provided.
  • Step 2 Preparation of 5-((5-chloropyridin-2-yl)methoxy)-l,3,4-thiadiazol-2-amine
  • a solution ofNaH (65.7 g, 1.64 mol, 60.0% purity) in THF (1.20 L) was added a solution of (5-chloropyridin-2-yl)methanol (158 g, 1.10 mol) in THF (400 mL) at 5 °C dropwise.
  • the mixture was stirred at 5 °C for 1 h.
  • 2-amino-5-bromo-l,3,4-thiadiazole (237 g, 1.31 mol) was added in portions at 5 °C.
  • the mixture was stirred at 5 °C for 4 h.
  • Step 1 methyl 4-chloro-6-methylnicotinate
  • 4-chloro-6-methylnicotinic acid 5.0 g, 29.1 mmol
  • dichloromethane 100 mL
  • methanol 10 mL
  • (diazomethyl)trimethylsilane 29 mL, 58.3 mmol
  • Step 2 methyl 4-(2-methoxyphenyl)-6-methylnicotinate
  • methyl 4-chloro-6-methylnicotinate 500.0 mg, 2.69 mmol
  • 2- methoxyphenylboronic acid 819.0 mg, 5.39 mmol
  • 1,4-Dioxane 1 mL
  • water 0.2 mL
  • (l,l'-Bis(diphenylphosphino)ferrocene)dicliloropalladium(II) 591.0 mg, 0.81 mmol
  • potassium carbonate 1.1 g, 8.08 mmol
  • Step- 1 2-bromo- 1 -(difluoromethoxy)-3 -fluorobenzene
  • Step-2 2-(2-(difhioromethoxy)-6-fluorophenyl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane
  • Step-3 methyl 4-(2-(difluoromethoxy)-6-fhiorophenyl)-6-methylpyridine-3-carboxylate
  • Step-4 4-(2-(difhioromethoxy)-6-fhiorophenyl)-6-methylpyridine-3-carboxylic acid
  • methyl 4-(2-(difluoromethoxy)-6-fluorophenyl)-6-methylpyridine-3- carboxylate 470.00 mg, 1.51 mmol
  • water 3.00 mF
  • LiOHThO 253.68 mg, 6.040 mmol
  • the resulting mixture was stirred at room temperature for 16 h.
  • the organic solvent was removed under vacuum and then diluted with water.
  • the solution was acidified by HC1 (1 N) to pH -6.
  • the resulting mixture was extracted with ethyl acetate.
  • Step 1 benzyl 4-chloro-6-methylnicotinate
  • a mixture of 4-chloro-6-methylpyridine-3-carboxylic acid (10.00 g, 58.3 mmol) and CS 2 CO3 (37.98 g, 116.6 mmol) in DMF (100 mL) was added benzyl bromide (14.95 g, 87.45 mmol).
  • the resulting mixture was stirred at room temperature for 16 h.
  • the reaction mixture was quenched with water and extracted with ethyl acetate.
  • the combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum.
  • Step 2 benzyl 2'-chloro-5'-methoxy-6-methyl-(4,4'-bipyridine)-3-carboxylate To a degassed mixture of methyl benzyl 4-chloro-6-methylpyridine-3-carboxylate (6.00 g,
  • Step-3 2-chloro-5-methoxy-6-methyl-(4,4-bipyridine)-3-carboxylic acid
  • Step 1 S-methyl 0-(prop-2-yn-l-yl) carbonodithioate
  • Step 3 5 -(prop-2 -yn-l-yloxy)-l, 3, 4-thiadiazol-2 -amine
  • Step 4 3-(2-methoxyphenyl)-N-(5-(prop-2-yn-l-yloxy)-l,3,4-thiadiazol-2-yl)isonicotinamide
  • DIEA 8.45 g, 0.65 mmol, 3.00 equiv
  • HATU 9.94 mg, 0.26 mmol, 1.20 equiv
  • Step-1 N-(5-((5-chloropyridin-2-yl)methoxy)-l,3,4-thiadiazol-2-yl)-4-(2-fluoro-6- methoxyphenyl)-6-methylnicotinamide
  • Step-2 4-(2-fluoro-6-methoxyphenyl)-N-(5-hydroxy-l,3,4-thiadiazol-2-yl)-6- methylnicotinamide
  • Step 4 4-(2-fluoro-6-methoxyphenyl)-6-methyl-N-(5-(3,3,3-trifluoro-2,2-dimethylpropoxy)- l,3,4-thiadiazol-2-yl)pyridine-3-carboxamide
  • the resulting mixture was purified by prep-HPLC with the following conditions: (Column: XBridge Prep OBD C18 Column, 30 150mm 5um; Mobile Phase A: Water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 60 mL/min; Gradient: 42% B to 57% B in 8 min, UV: 254 nm) to afford 4-(2-fluoro-6-methoxyphenyl)-6-methyl-N-(5-(3,3,3-trifluoro- 2,2-dimethylpropoxy)-l,3,4-thiadiazol-2-yl)pyridine-3-carboxamide (23.2 mg, 23%) as a white solid.
  • Step-1 ((isopropoxymethanethioyl)amino)amine
  • Step-2 5-isopropoxy-l,3,4-thiadiazol-2-amine
  • Step-3 2'-chloro-N-(5-isopropoxy-l,3,4-thiadiazol-2-yl)-5'-methoxy-6-methyl-(4,4'- bipyridine)-3 -carboxamide
  • Step 4 2'-chloro-N-(5-cyclopropoxy-l,3,4-thiadiazol-2-yl)-5'-methoxy-6-methyl-(4,4'- bipyridine)-3 -carboxamide
  • the resulting mixture was purified by Prep-HPLC with the following conditions: (Column: YMC- Actus Triart C18 ExRS, 30 mm X 150 mm, 5 um; Mobile Phase A: Water (10 MMOL/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 60 mL/min; Gradient: 25% B to 40% B in 8 min, 40% B to 95% B in 9 min, 95% B to 95% B in 9.5 min, 95% B to 5% B in 10 min;
  • Step 3 4-(5-chloro-2-methoxyphenyl)-N-(5-methoxy- l,3,4-thiadiazol-2-yl)-6- methylnicotinamide
  • Step-1 3-((5-amino-l,3,4-thiadiazol-2-yl)oxy)-2,2-dimethylpropanenitrile
  • Step-2 2'-chloro-N-(5-(2-cyano-2-methylpropoxy)-l,3,4-thiadiazol-2-yl)-5'-methoxy-6- methyl-(4,4'-bipyridine)-3-carboxamide
  • Intermediate G 70.0 mg, 0.25 mmol
  • 3-((5-amino-l,3,4-thiadiazol-2- yl)oxy)-2,2-dimethylpropanenitrile (50.0 mg, 0.25 mmol) in N,N-Dimethylformamide (2 mL) were added DIEA (98 mg, 0.76 mmol) and HATU (142.5 mg, 037 mmol) at 20 °C .
  • DIEA 98 mg, 0.76 mmol
  • HATU 142.5 mg, 037 mmol
  • Step 2 2'-chloro-N-(5-cyclobutoxy-l,3,4-thiadiazol-2-yl)-5'-methoxy-6-methyl-(4,4'- bipyridine)-3 -carboxamide
  • Step 4 2'-chloro-N-(5-(cyclohexyloxy)-l,3,4-thiadiazol-2-yl)-5'-methoxy-6-methyl-(4,4'- bipyridine)-3 -carboxamide
  • 5-(oxetan-3-yloxy)-l,3,4-thiadiazol-2-amine 100.0 mg, 0.58 mmol
  • N,N- dimethylformamide 1 mL
  • acetonitrile (1 mL)
  • Step-1 methyl 2-((5-amino-l,3,4-thiadiazol-2-yl)oxy)acetate
  • Step-2 methyl 2-((5-(2’-chloro-5’-methoxy-6-methyl-(4,4’-bipyridine)-3-carboxamido)- 1 ,3 ,4-thiadiazol-2-yl)oxy)acetate
  • Step-3 2’-chloro-N-(5-(2-hydroxy-2-methylpropoxy)-l,3,4-thiadiazol-2-yl)-5’-methoxy-6- methyl-(4,4’-bipyridine)-3-carboxamide
  • Step 1 0-(3-(benzyloxy)cyclobutyl) S-methyl carbonodithioate To a solution ofNaH (242 mg, 6.06 mmol, 60%) in THF (5 mL) was added a solution of 3- (benzyloxy)cyclobutan-l-ol (900 mg, 5.06 mmol) in THF (5 mL) dropwise at 0 °C. The resulting mixture was stirred at 0 °C for 30 min. To the above mixture was added CS2 (576 mg, 7.59 mmol) dropwise at 0 °C and stirred at 0 °C for 20 min. Then Mel (1.07 mg, 7.59 mmol) was added to the above mixture dropwise at 0 °C.
  • the resulting mixture was stirred at room temperature for 1 hour.
  • the resulting mixture was quenched with water.
  • the aqueous layer was extracted with ethyl acetate.
  • the organic layers were combined, washed with brine, dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under vacuum.
  • Step 5 2'-chloro-N-(5-(3-hydroxycyclobutoxy)-l,3,4-thiadiazol-2-yl)-5'-methoxy-6-methyl- (4,4'-bipyridine)-3-carboxamide
  • Step 6 2'-chloro-N-(5-((ls,3s)-3-hydroxycyclobutoxy)-l,3,4-thiadiazol-2-yl)-5'-methoxy-6- methyl-(4,4'-bipyridine)-3-carboxamide and 2'-chloro-N-(5 -(( lr,3r)-3-hydroxycyclobutoxy)- l,3,4-thiadiazol-2-yl)-5'-methoxy-6-methyl-(4,4'-bipyridine)-3-carboxamide
  • Step 4 2'-chloro-N-(5-(cyclopentyloxy)-l,3,4-thiadiazol-2-yl)-5'-methoxy-6-methyl-(4,4'- bipyridine)-3 -carboxamide
  • the reaction mixture (3 mL) was purified by prep-HPLC with the following conditions: (Column: XBridge Shield RP18 OBD Column, 30*150 mm, 5pm; Mobile Phase A: Water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 60 mL/min; Gradient: 34% B to 50% B in 8 min, 50% B to 95% B in 8.2 min, 95% B to 95% B in 9.5 min, 95% B to 5% B in 11 min, 5% B; Wave Length: 254 nm; RT1 (min): 6; Injection Volume: 0.5 mL; Number Of Runs: 5) to afford 2'- chloro-N-(5-(cyclopentyloxy)-l,3,4-thiadiazol-2-yl)-5'-methoxy-6-methyl-(4,4'-bipyridine)- 3-carboxamide (51.7 mg, 10% yield) as a white solid MS (ESI) calc’d for
  • Step-1 5-(2-fluoro-2-methylpropoxy)-l,3,4-thiadiazol-2-amine
  • Step-2 2'-chloro-N-(5-(2-fluoro-2-methylpropoxy)-l,3,4-thiadiazol-2-yl)-5'-methoxy-6- methyl-(4,4'-bipyridine)-3-carboxamide
  • Phase A Water (10 mmol/L NH4HCO3), Mobile Phase B: MeOH - Preparative; Flow rate: 60 mL/min; Gradient: 50% B to 70% B in 8 min, 70% B; Wave Length: 254 nm; RT1 (min):
  • Step-2 6'-chloro-N-(5-(2,2-difluoropropoxy)-l,3,4-thiadiazol-2-yl)-3'-methoxy-6-methyl- 4,4'-bipyridine-3-carboxamide
  • Step-1 5-isobutoxy- l,3,4-thiadiazol-2-amine
  • Step-2 2'-chloro-N-(5-isobutoxy-l,3,4-thiadiazol-2-yl)-5'-methoxy-6-methyl-(4,4'- bipyridine)-3 -carboxamide
  • Step 2 2'-chloro-5'-methoxy-6-methyl-N-(5-((tetrahydrofuran-3-yl)oxy)- l,3,4-thiadiazol-2- yl)-(4,4'-bipyridine)-3-carboxamide
  • Step 3 (S)-2'-chloro-5'-methoxy-6-methyl-N-(5-((tetrahydrofuran-3-yl)oxy)-l,3,4-thiadiazol- 2-yl)-(4,4'-bipyridine)-3-carboxamide and (R)-2'-chloro-5'-methoxy-6-methyl-N-(5- ((tetrahydrofuran-3-yl)oxy)-l,3,4-thiadiazol-2-yl)-(4,4'-bipyridine)-3-carboxamide
  • Step-1 5-((3-methyloxetan-3-yl)oxy)-l,3,4-thiadiazol-2-amine
  • Step-2 2'-chloro-5'-methoxy-6-methyl-N-(5-((3-methyloxetan-3-yl)oxy)-l,3,4-thiadiazol-2- yl)-(4,4'-bipyridine)-3-carboxamide
  • Step 1 0-(l,l-dioxidotetrahydro-2H-thiopyran-4-yl) S-methyl carbonodithioate
  • the resulting mixture was then stirred at 23 °C for 2 hr.
  • the reaction mixture was quenched by the addition of water and extracted with ethyl acetate.
  • the combined organic layers were washed with brine, dried over anhydrous sodium sulfate, fdtered, and concentrated under vacuum.
  • Step 3 4-((5-amino-l,3,4-thiadiazol-2-yl)oxy)tetrahydro-2H-thiopyran 1,1 -dioxide
  • Step 4 2'-chloro-N-(5-(( 1 , 1 -dioxidotetrahydro-2H-thiopyran-4-yl)oxy)- 1 ,3,4-thiadiazol-2-yl)- 5'-methoxy-6-methyl-(4,4'-bipyridine)-3-carboxamide
  • Step 1 0-(4-((tert-butyldimethylsilyl)oxy)cyclohexyl) S-methyl carbonodithioate
  • Step 2 0-(4-((tert-butyldimethylsilyl)oxy)cyclohexyl) hydrazinecarbothioate
  • Step 4 N-(5-((4-((tert-butyldimethylsilyl)oxy)-l,3,4-thiadiazol-2-yl)-2'- chloro-5'-methoxy-6-methyl-(4,4'-bipyridine)-3-carboxamide
  • Step 5 2'-chloro-N-(5-(((ls,4s)-4-hydroxycyclohexyl)oxy)-l,3,4-thiadiazol-2-yl)-5'-methoxy- 6-methyl-[4,4'-bipyridine]-3-carboxamide, and 2'-chloro-N-(5-(((lr,4r)-4- hydroxycyclohexyl)oxy)-l,3,4-thiadiazol-2-yl)-5'-methoxy-6-methyl-[4,4'-bipyridine]-3- carboxamide
  • Step-1 O-ethyl hydrazinecarbothioate
  • Step-2 5 -ethoxy- 1 ,3 ,4-thiadiazol -2-amine
  • Step-3 2'-chloro-N-(5-ethoxy-l,3,4-thiadiazol-2-yl)-5'-methoxy-6-methyl-(4,4'-bipyridine)- 3 -carboxamide
  • Step-1 5-(2,2,2-trifluoroethoxy)-l,3,4-thiadiazol-2-amine
  • Step-2 2'-chloro-5'-methoxy-6-methyl-N-(5-(2,2,2-trifluoroethoxy)-l,3,4-thiadiazol-2-yl)- (4,4'-bipyridine)-3-carboxamide
  • Step-2 4-(2-methoxy-5 -methylphenyl)-6-methylpyridine-3 -carboxylic acid
  • Step-3 N-(5-methoxy-l,3,4-thiadiazol-2-yl)-4-(2-methoxy-5-methylphenyl)-6- methylnicotinamide
  • the mixture was diluted with DMF (2 mL) and was purified by prep-HPLC with the following conditions: (Column: XBridge Shield RP18 OBD Column, 30* 150 mm, 5pm; Mobile Phase A: Water (10 mmol/L NH4HC03), Mobile Phase B: ACN; Flow rate: 60 mL/min; Gradient: 27% B to 43% B in 8 min, 43% B to 95% B in 8.2 min, 95% B to 95% B in 9.5 min, 95% B to 5% B in 11 min, 5% B; Wave Length: 254 nm; RTl(min): 7.4; Injection Volume: 0.5 mL; Number Of Runs: 5) to afford N-(5-methoxy-l,3,4-thiadiazol-2-yl)-4-(2-methoxy-5-methylphenyl)-6- methylnicotinamide (72.6 mg, 50%) as a white solid.
  • Step-1 2'-chloro-N-(5-((5-chloropyridin-2-yl)methoxy)-l,3,4-thiadiazol-2-yl)-5methoxy-6- methyl-(4,4'-bipyridine)-3-carboxamide
  • Step-2 2'-chloro-N-(5-hydroxy-l,3,4-thiadiazol-2-yl)-5'-methoxy-6-methyl-(4,4'-bipyridine)- 3 -carboxamide
  • a solution of 2'-chloro-N-(5-((5-chloropyridin-2-yl)methoxy)-l,3,4-thiadiazol-2-yl)-5'- methoxy-6-methyl-(4,4'-bipyridine)-3-carboxamide (320.0 mg, 0.64 mmol) in concentrated hydrochloric acid (1 mL) was stirred at 20 °C for 1 hr. The mixture was diluted with water.
  • Step-1 2-(5-chloro-2-(difluoromethoxy)phenyl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane
  • Step-2 methyl 4-(5-chloro-2-(difluoromethoxy)phenyl)-6-methylnicotinate
  • Step-3 4-(5-chloro-2-(difluoromethoxy)phenyl)-6-methylnicotinic acid
  • Step-4 4-(5-chloro-2-(difluoromethoxy)phenyl)-N-(5-methoxy-l,3,4-thiadiazol-2-yl)-6- methylnicotinamide
  • Step-1 methyl 4-(2,6-dichlorophenyl)-6-methylnicotinate
  • Step-3 4-(2,6-dichlorophenyl)-N-(5-methoxy-l,3,4-thiadiazol-2-yl)-6-methylnicotinamide
  • Step-1 methyl 4-(2-chloro-6-methoxyphenyl)-6-methylnicotinate
  • Step-2 4-(2-chloro-6-methoxyphenyl)-6-methylnicotinic acid
  • Step-3 4-(2-chloro-6-methoxyphenyl)-N-(5-methoxy-l,3,4-thiadiazol-2-yl)-6- methylnicotinamide
  • 4-(2-chloro-6-methoxyphenyl)-6-methylnicotinic acid (300.0 mg, 1.08 mmol) in acetonitrile (2 mL) were sequentially added 5-methoxy-l,3,4-thiadiazol-2- amine (156.0 mg, 1.19 mmol) and 1-Methylimidazole (443.0 mg, 5.40 mmol) at 17 °C.
  • Step-2 4-(2-(difluoromethoxy)phenyl)-6-methylnicotinic acid
  • Step-3 4-(2-(difluoromethoxy)phenyl)-N-(5-methoxy-l,3,4-thiadiazol-2-yl)-6- methylnicotinamide
  • Step 3 4-(2-chloro-6-fhiorophenyl)-N-(5-methoxy-l,3,4-thiadiazol-2-yl)-6- methylnicotinamide
  • 4-(2-chloro-6-fluorophenyl)-6-methylnicotinic acid 80.0 mg, 0.30 mmol
  • Acetonitrile 2 mL
  • 5-methoxy-l,3,4-thiadiazol-2-amine 39.5 mg, 0.30 mmol
  • 1-methylimidazole (124.2 mg, 1.50 mmol
  • Step-1 methyl 2'-chloro-5',6-dimethyl-(4,4'-bipyridine)-3-carboxylate
  • Step-2 2'-chloro-5',6-dimethyl-(4,4'-bipyridine)-3-carboxylic acid
  • Step-3 2'-chloro-N-(5-methoxy-l,3,4-thiadiazol-2-yl)-5',6-dimethyl-(4,4'-bipyridine)-3- carboxamide
  • Step- 1 methyl 4-(3,5-dimethyl- lH-pyrazol-4-yl)-6-methylnicotinate
  • Step-2 4-(3,5-dimethyl-4H-pyrazol-4-yl)-6-methylnicotinic acid
  • Step-3 4-(3,5-dimethyl-lH-pyrazol-4-yl)-N-(5-methoxy-l,3,4-thiadiazol-2-yl)-6- methylnicotinamide
  • Step-1 methyl 2',5'-dichloro-6-methyl-(4,4'-bipyridine)-3-carboxylate
  • Step-2 5'-chloro-2',6-dimethyl-(4,4'-bipyridine)-3-carboxylate
  • Step-3 5'-chloro-2',6-dimethyl-(4,4'-bipyridine)-3-carboxylic acid
  • Step-4 5'-chloro-N-(5-methoxy-l,3,4-thiadiazol-2-yl)-2',6-dimethyl-(4,4'-bipyridine)-3- carboxamide
  • Step 1 methyl 4-(6-chloro-3-methoxypyridazin-4-yl)-6-methylnicotinate
  • Step-2 methyl 4-(3-methoxy-6-methylpyridazin-4-yl)-6-methylnicotinate
  • Step-3 4-(3-methoxy-6-methylpyridazin-4-yl)-6-methylnicotinic acid
  • Step-4 N-(5-methoxy-l,3,4-thiadiazol-2-yl)-4-(3-methoxy-6-methylpyridazin-4-yl)-6- methylnicotinamide
  • Step-2 methyl 2'-ethyl-5'-methoxy-6-methyl-(4,4'-bipyridine)-3-carboxylate
  • a mixture of methyl 5'-methoxy-6-methyl-2'-vinyl-(4,4'-bipyridine)-3-carboxylate (342.0 mg, 0.85 mmol) in Methanol (2 mL) was added Pd/C (dry, 50.0 mg) under hydrogen atmosphere.
  • the resulting solution was stirred at 20 °C for 2 hr under hydrogen atmosphere.
  • the suspension was filtered.
  • the filtrate was collected and concentrated under vacuum.
  • Step-3 2'-ethyl-5'-methoxy-6-methyl-(4,4'-bipyridine)-3-carboxylic acid
  • Step-4 2'-ethyl-5'-methoxy-N-(5-methoxy-l,3,4-thiadiazol-2-yl)-6-methyl-(4,4'-bipyridine)- 3 -carboxamide
  • the product (70%) was dissolved in DMF (5 mL) and further purified by prep-HPLC with the following conditions: (Column: XBridge Shield RP18 OBD Column, 30 * 150 mm, 5 pm; Mobile Phase A: Water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 60 mL/min; Gradient: 20% B to 40% B in 8 min, 40% B to 95% B in 8.2 min, 95% B to 95% B in 9.5 min, 95% B to 5% B in 11 min, 5% B; Wave Length: 254 nm; RTl(min): 5.6; Injection Volume: 1.5 mL; Number Of Runs: 3) to afford 2'-ethyl-5'-methoxy-N-(5-methoxy-l,3,4- thiadiazol-2-yl)-6-methyl-(4,4'-bipyridine)-3-carboxamide (51.1 mg, 29%) as a white solid.
  • Step 45 ((3-((tert-butyldimethylsilyl)oxy)cyclopentyl)oxy)-l ,3,4-thiadiazol-2-amine
  • methanol 4 mL
  • TEA 0.7 mL, 4.61 mmol
  • BrCN 366.0 mg, 3.46 mmol
  • Step 5 2-(5-((3-((tert-butyldimethylsilyl)oxy)cyclopentyl)oxy)-l,3,4-thiadiazol-2-yl)-l-(2'- chloro-5'-methoxy-6-methyl-(4,4'-bipyridin)-3-yl)ethan-l-one
  • Step-2 2-chloro-3-fluoro-4-iodo-5-methoxypyridine
  • reaction mixture was quenched by the addition of saturated sodium thiosulfate aqueous solution and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum.
  • Step-3 methyl 2'-chloro-3'-fluoro-5'-methoxy-6-methyl-(4,4'-bipyridine)-3-carboxylate
  • Step-4 2'-chloro-3'-fluoro-5'-methoxy-6-methyl-(4,4'-bipyridine)-3-carboxylic acid
  • Step-5 2'-chloro-3'-fluoro-5'-methoxy-N-(5-methoxy-l,3,4-thiadiazol-2-yl)-6-methyl-(4,4'- bipyridine)-3 -carboxamide
  • To a solution of 2'-chloro-3'-fluoro-5'-methoxy-6-methyl-(4,4'-bipyridine)-3-carboxylic acid (130.0 mg, 0.43 mmol) in dry acetonitrile (1 mL) were added 5-methoxy-l,3,4-thiadiazol-2- amine (57.0 mg, 0.43 mmol) and 1 -methyl- lH-imidazole (180.0 mg, 2.15 mmol) at 25 °C.
  • Step-1 2-chloro-5-(difluoromethoxy)-4-iodopyridine
  • Step-2 methyl 2'-chloro-5'-(difhioromethoxy)-6-methyl-(4,4'-bipyridine)-3-carboxylate
  • Step-3 2'-chloro-5'-(difluoromethoxy)-6-methyl-(4,4'-bipyridine)-3-carboxylic acid
  • Step-4 2'-chloro-5'-(difluoromethoxy)-N-(5-methoxy-l,3,4-thiadiazol-2-yl)-6-methyl-(4,4'- bipyridine)-3 -carboxamide
  • Step-2 methyl 2'-chloro-6-methyl-5'-vinyl-(4,4'-bipyridine)-3-carboxylate
  • methyl 5'-bromo-2'-chloro-6-methyl-(4,4'-bipyridine)-3-carboxylate 400.0 mg, 1.17 mmol
  • 4,4,5,5-tetramethyl-2-vinyl-l,3,2-dioxaborolane 180.0 mg, 1.17 mmol
  • Toluene (2 mL) was added I,G-Bis (di-t-butylphosphino)ferrocene palladium dichloride (76.0 mg, 0.12 mmol) at 20 °C under nitrogen atmosphere.
  • Step-3 methyl 2'-chloro-5'-ethyl-6-methyl-(4,4'-bipyridine)-3-carboxylate
  • Step-4 2'-chloro-5'-ethyl-6-methyl-(4,4'-bipyridine)-3-carboxylic acid
  • Step-5 2'-chloro-5'-ethyl-N-(5-methoxy-l,3,4-thiadiazol-2-yl)-6-methyl-(4,4'-bipyridine)-3- carboxamide
  • Step-1 methyl 7-chloroimidazo(l,2-a)pyridine-6-carboxylate
  • Step-2 methyl 7-(2-fluoro-6-methoxyphenyl)imidazo(l,2-a)pyridine-6-carboxylate
  • Step-3 7-(2-fluoro-6-methoxyphenyl)imidazo(l,2-a)pyridine-6-carboxylic acid
  • Step-4 7-(2-fluoro-6-methoxyphenyl)-N-(5-methoxy-l,3,4-thiadiazol-2-yl)imidazo(l,2- a)pyridine-6-carboxamide
  • 7-(2-fluoro-6-methoxyphenyl)imidazo(l,2-a)pyridine-6-carboxylic acid 700.0 mg, 0.24 mmol
  • Acetonitrile 3 mL
  • 5-methoxy-l,3,4-thiadiazol-2- amine 38.5 mg, 0.29 mmol
  • NI 120.0 mg, 1.46 mmol
  • Step-1 methyl 2'-cyclopropyl-5'-methoxy-6-methyl-(4,4'-bipyridine)-3-carboxylate
  • Step-2 2'-cyclopropyl-5'-methoxy-6-methyl-(4,4'-bipyridine)-3-carboxylic acid
  • a stirred solution of methyl 2'-cyclopropyl-5'-methoxy-6-methyl-(4,4'-bipyridine)-3- carboxylate (300.0 mg, 1.01 mmol) in Tetrahydrofuran (2 mL) was added a solution of lithium hydroxide (24.1 mg, 1.01 mmol) in Water (2 mL) at 20 °C.
  • the resulting solution was stirred at 20 °C for 1 hr.
  • the organic solvent was removed under vacuum.
  • the aqueous layer was acidified with citric acid to pH -5 and extracted with ethyl acetate.
  • Step-3 2'-cyclopropyl-5'-methoxy-N-(5-methoxy-l,3,4-thiadiazol-2-yl)-6-methyl-(4,4'- bipyridine)-3 -carboxamide
  • Step 3 5'-(difluoromethoxy)-N-(5-methoxy- l,3,4-thiadiazol-2-yl)-2',6-dimethyl-(4,4'- bipyridine)-3 -carboxamide
  • Step 1 methyl 4-(5-chloro-2-ethoxyphenyl)-6-methylnicotinate
  • methyl 4-chloro-6-methylnicotinate 500.0 mg, 2.56 mmol
  • 1,4-Dioxane 8 mL
  • 5-chloro-2-ethoxyphenyl) boronic acid 513.0 mg, 2.56 mmol
  • Pd(dppf)Ch 209.0 mg, 0.25 mmol
  • K2CO3 707.0 mg, 5.12 mmol
  • Water 2 mL
  • Step 3 4-(5-chloro-2-ethoxyphenyl)-N-(5-methoxy-l,3,4-thiadiazol-2-yl)-6- methylnicotinamide
  • Step-2 2-(2-chloro-6-(difluoromethoxy)phenyl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane
  • Step-3 methyl 4-(2-chloro-6-(difluoromethoxy)phenyl)-6-methylnicotinate
  • Step-4 4-(2-chloro-6-(difluoromethoxy)phenyl)-6-methylnicotinic acid
  • Step 1 methyl 2'-chloro-5',6-dimethyl-(4,4'-bipyridine)-3-carboxylate
  • 4-bromo-2-chloro-5-methylpyridine 1.0 g, 4.84 mmol
  • 1,4- Dioxane 8 mL
  • methyl 6-methyl-4-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)nicotinate 1.3 g, 4.84 mmol
  • water 1.6 mL
  • K2CO3 2.0 g, 14.53 mmol
  • Step-1 5-methoxy-2-(trifluoromethyl)pyridine
  • Step-2 4-iodo-5 -methoxy-2-(trifluoromethyl)pyridine
  • Step-3 methyl 5'-methoxy-6-methyl-2'-(trifhioromethyl)-(4,4'-bipyridine)-3-carboxylate

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
PCT/IB2022/055384 2021-06-11 2022-06-09 O-linked thiadiazolyl compounds as dna polymerase theta inhibitors Ceased WO2022259204A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
US18/567,687 US20240287080A1 (en) 2021-06-11 2022-06-09 O-linked thiadiazolyl compounds as dna polymerase theta inhibitors
KR1020247000980A KR20240044412A (ko) 2021-06-11 2022-06-09 Dna 폴리머라제 세타 억제제로서의 o-연결된 티아디아졸릴 화합물
MX2023014665A MX2023014665A (es) 2021-06-11 2022-06-09 Compuestos de tiadiazolilo unidos a un atomo de oxigeno como inhibidores de dna polimerasa (theta).
AU2022289762A AU2022289762B2 (en) 2021-06-11 2022-06-09 O-linked thiadiazolyl compounds as dna polymerase theta inhibitors
EP22735990.8A EP4352055A1 (en) 2021-06-11 2022-06-09 O-linked thiadiazolyl compounds as dna polymerase theta inhibitors
JP2023576009A JP2024522373A (ja) 2021-06-11 2022-06-09 Ｄｎａポリメラーゼシータ阻害剤としてのｏ結合チアジアゾリル化合物
BR112023025245A BR112023025245A2 (pt) 2021-06-11 2022-06-09 Compostos de tiadiazolil o-ligados como inibidores de dna polimerase theta
IL308912A IL308912A (en) 2021-06-11 2022-06-09 O-linked THIADIAZOLYL compounds as inhibitors of DNA polymerase theta
CN202280054416.4A CN117794927A (zh) 2021-06-11 2022-06-09 作为DNA聚合酶θ抑制剂的O-连接噻二唑基化合物
CA3222078A CA3222078A1 (en) 2021-06-11 2022-06-09 O-linked thiadiazolyl compounds as dna polymerase theta inhibitors
CONC2023/0017082A CO2023017082A2 (es) 2021-06-11 2023-12-07 Compuestos de tiadiazolilo unidos a un átomo de oxígeno como inhibidores de dna polimerasa θ

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163209555P 2021-06-11 2021-06-11
US63/209,555 2021-06-11
US202263319826P 2022-03-15 2022-03-15
US63/319,826 2022-03-15

Publications (1)

Publication Number Publication Date
WO2022259204A1 true WO2022259204A1 (en) 2022-12-15

Family

ID=82358548

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2022/055384 Ceased WO2022259204A1 (en) 2021-06-11 2022-06-09 O-linked thiadiazolyl compounds as dna polymerase theta inhibitors

Country Status (13)

Country Link
US (1) US20240287080A1 (https=)
EP (1) EP4352055A1 (https=)
JP (1) JP2024522373A (https=)
KR (1) KR20240044412A (https=)
AU (1) AU2022289762B2 (https=)
BR (1) BR112023025245A2 (https=)
CA (1) CA3222078A1 (https=)
CL (1) CL2023003671A1 (https=)
CO (1) CO2023017082A2 (https=)
IL (1) IL308912A (https=)
MX (1) MX2023014665A (https=)
TW (1) TW202315618A (https=)
WO (1) WO2022259204A1 (https=)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023202623A1 (zh) * 2022-04-20 2023-10-26 南京再明医药有限公司 Polq抑制剂化合物及其应用
WO2024069592A1 (en) * 2022-09-29 2024-04-04 Repare Therapeutics Inc. N-(5-substituted-[(l,3,4-thiadiazolyl) or (l,3-thiazolyl)](substituted)carboxamide compounds, pharmaceutical compositions, and methods of preparing the amide compounds and of their use
WO2024088407A1 (zh) * 2022-10-28 2024-05-02 杭州圣域生物医药科技有限公司 并环含氮化合物、其中间体、制备方法和应用
WO2024099336A1 (en) * 2022-11-10 2024-05-16 Danatlas Pharmaceuticals Co., Ltd. Thiadiazolyl derivatives, compositions and uses thereof
WO2024121290A1 (en) * 2022-12-09 2024-06-13 Glaxosmithkline Intellectual Property (No.4) Limited Thiadiazolyl derivatives as dna polymerase theta inhibitors and uses thereof
WO2024149349A1 (zh) * 2023-01-14 2024-07-18 西藏海思科制药有限公司 靶向Polθ的化合物及其用途
WO2024182382A1 (en) * 2023-02-28 2024-09-06 Cyteir Therapeutics, Inc. 4,5-fused bicyclic pyrrolidine and 4,5-fused bicyclic pyrrolidinone compounds
WO2024189493A1 (en) * 2023-03-10 2024-09-19 Breakpoint Therapeutics Gmbh Inhibitors of dna polymerase theta
WO2024213082A1 (en) * 2023-04-13 2024-10-17 Danatlas Pharmaceuticals Co., Ltd. Thiadiazolone derivatives, compositions and uses thereof
WO2024245415A1 (zh) * 2023-06-02 2024-12-05 成都微芯药业有限公司 Polθ抑制剂及其制备方法和用途
WO2024245310A1 (en) * 2023-05-30 2024-12-05 Ningbo Newbay Technology Development Co., Ltd. Thiazolyl or thiadiazolyl amides derivatives and use thereof
WO2025011617A1 (zh) * 2023-07-12 2025-01-16 杭州圣域生物医药科技有限公司 并环杂芳环类化合物、其中间体、制备方法和应用
WO2025016391A1 (zh) * 2023-07-18 2025-01-23 南京再明医药有限公司 噻唑并吡嗪类化合物及其应用
WO2025021198A1 (en) * 2023-07-27 2025-01-30 Danatlas Pharmaceuticals Co., Ltd. PolQ DEGRADERS, COMPOSITIONS AND USES THEREOF
WO2024259233A3 (en) * 2023-06-16 2025-02-20 Quantx Biosciences Us, Inc. Fused bicyclic heterocyclic or hetero aryl amide compounds
WO2025036490A1 (zh) * 2023-08-17 2025-02-20 海思科医药集团股份有限公司 一种DNA聚合酶θ抑制剂及其用途
WO2025045248A1 (zh) * 2023-09-01 2025-03-06 杭州圣域生物医药科技有限公司 联芳环类化合物、其中间体、制备方法和应用
WO2025110780A1 (en) * 2023-11-24 2025-05-30 Daewoong Pharmaceutical Co., Ltd. Novel heterocyclic compounds and pharmaceutical composition comprising the same as dna polymerase theta inhibitors for the prevention or treatment of cancer
WO2025165092A1 (en) * 2024-01-30 2025-08-07 Daewoong Pharmaceutical Co., Ltd. Novel heterocyclic compounds and pharmaceutical composition comprising the same as dna polymerase theta inhibitors for the prevention or treatment of cancer
WO2025223483A1 (zh) * 2024-04-24 2025-10-30 杭州圣域生物医药科技有限公司 并环含氮化合物、其晶型及其制备方法和用途
WO2025223472A1 (zh) * 2024-04-24 2025-10-30 杭州圣域生物医药科技有限公司 一种并环含氮化合物及其中间体的制备方法
WO2025223471A1 (zh) * 2024-04-24 2025-10-30 杭州圣域生物医药科技有限公司 一种并环含氮化合物及其中间体的制备方法
US12559508B2 (en) 2023-04-05 2026-02-24 Moma Therapeutics, Inc. Semi-saturated bicyclic derivatives and related uses
JP2026507092A (ja) * 2023-02-28 2026-02-27 レグラジーン、インコーポレイテッド 健康状態の治療のための小分子を作製および使用するための組成物および方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117229260B (zh) * 2023-11-13 2024-02-27 中国药科大学 DNA聚合酶θ与聚ADP核糖聚合酶1双靶点抑制剂及其制备方法和医药用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011065402A1 (ja) * 2009-11-25 2011-06-03 日本たばこ産業株式会社 インドール化合物及びその医薬用途
EP3034500A1 (en) * 2014-12-17 2016-06-22 Genkyotex Sa Amido thiazole derivatives as NADPH oxidase inhibitors
WO2020243459A1 (en) * 2019-05-31 2020-12-03 Ideaya Biosciences, Inc. Thiadiazolyl derivatives as dna polymerase theta inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7737149B2 (en) * 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
USRE50319E1 (en) * 2017-10-16 2025-03-04 Dana-Farber Cancer Institute, Inc. Compounds and methods for treating cancer
TW202237595A (zh) * 2020-12-02 2022-10-01 美商愛德亞生物科學公司 作為DNA聚合酶θ抑制劑之經取代噻二唑基衍生物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011065402A1 (ja) * 2009-11-25 2011-06-03 日本たばこ産業株式会社 インドール化合物及びその医薬用途
EP3034500A1 (en) * 2014-12-17 2016-06-22 Genkyotex Sa Amido thiazole derivatives as NADPH oxidase inhibitors
WO2020243459A1 (en) * 2019-05-31 2020-12-03 Ideaya Biosciences, Inc. Thiadiazolyl derivatives as dna polymerase theta inhibitors

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
AUDEH M. W. ET AL., LANCET, vol. 376, no. 9737, 2010, pages 245 - 51
BERGE, S.M. ET AL.: "Pharmaceutical Salts", JOURNAL OF PHARMACEUTICAL SCIENCE, vol. 66, 1977, pages 1 - 19, XP002675560, DOI: 10.1002/jps.2600660104
CHAN S. H. ET AL., PLOS GENET., vol. 6, no. 100, 2010, pages 1005
KAWAMURA K ET AL., INT. J. CANCER, vol. 109, 2004, pages 9 - 16
KENT T. ET AL., ELIFE, vol. 5, 2016, pages e13740
KENT T. ET AL., NAT. STRUCT. MOL. BIOL., vol. 22, 2015, pages 230 - 237
LEMEE F ET AL., PROC NATL ACAD SCI USA., vol. 107, 2010, pages 13390 - 5
MATEOS-GOMEZ P. A. ET AL., NATURE, vol. 518, 2015, pages 254 - 57
ROERINK S. F. ET AL., GENOME RESEARCH., vol. 24, 2014, pages 954 - 962
TATIANA KENT ET AL: "DNA polymerase specializes in incorporating synthetic expanded-size (xDNA) nucleotides", NUCLEIC ACIDS RESEARCH, vol. 44, no. 19, 1 January 2016 (2016-01-01), GB, pages 9381 - 9392, XP055530119, ISSN: 0305-1048, DOI: 10.1093/nar/gkw721 *
WYATT D.W. ET AL., MOL. CELL, vol. 63, 2016, pages 662 - 73

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023202623A1 (zh) * 2022-04-20 2023-10-26 南京再明医药有限公司 Polq抑制剂化合物及其应用
WO2024069592A1 (en) * 2022-09-29 2024-04-04 Repare Therapeutics Inc. N-(5-substituted-[(l,3,4-thiadiazolyl) or (l,3-thiazolyl)](substituted)carboxamide compounds, pharmaceutical compositions, and methods of preparing the amide compounds and of their use
AU2023368731B2 (en) * 2022-10-28 2025-12-18 Hangzhou Synrx Therapeutics Biomedical Technology Co., Ltd. Nitrogen-containing fused ring compound, intermediate thereof, preparation method therefor and use thereof
WO2024088407A1 (zh) * 2022-10-28 2024-05-02 杭州圣域生物医药科技有限公司 并环含氮化合物、其中间体、制备方法和应用
WO2024099336A1 (en) * 2022-11-10 2024-05-16 Danatlas Pharmaceuticals Co., Ltd. Thiadiazolyl derivatives, compositions and uses thereof
US12398131B2 (en) * 2022-12-09 2025-08-26 Glaxosmithkline Intellectual Property (No. 4) Limited Thiadiazolyl derivatives as DNA polymerase theta inhibitors and uses thereof
WO2024121290A1 (en) * 2022-12-09 2024-06-13 Glaxosmithkline Intellectual Property (No.4) Limited Thiadiazolyl derivatives as dna polymerase theta inhibitors and uses thereof
WO2024149349A1 (zh) * 2023-01-14 2024-07-18 西藏海思科制药有限公司 靶向Polθ的化合物及其用途
WO2024182382A1 (en) * 2023-02-28 2024-09-06 Cyteir Therapeutics, Inc. 4,5-fused bicyclic pyrrolidine and 4,5-fused bicyclic pyrrolidinone compounds
JP2026507092A (ja) * 2023-02-28 2026-02-27 レグラジーン、インコーポレイテッド 健康状態の治療のための小分子を作製および使用するための組成物および方法
WO2024189493A1 (en) * 2023-03-10 2024-09-19 Breakpoint Therapeutics Gmbh Inhibitors of dna polymerase theta
US12145945B2 (en) 2023-03-10 2024-11-19 Breakpoint Therapeutics Gmbh Compounds, compositions, and therapeutic uses thereof
US12162895B2 (en) 2023-03-10 2024-12-10 Breakpoint Therapeutics Gmbh DNA polymerase theta inhibitor for treatment of cancer
WO2024197401A1 (en) * 2023-03-30 2024-10-03 Repare Therapeutics Inc. 1,3,4-thiadiazol-2-yl carboxamide and 1,3-thiazol-2-yl carboxamide compounds and uses thereof as inhibitors of human polymerase theta
US12559508B2 (en) 2023-04-05 2026-02-24 Moma Therapeutics, Inc. Semi-saturated bicyclic derivatives and related uses
WO2024213082A1 (en) * 2023-04-13 2024-10-17 Danatlas Pharmaceuticals Co., Ltd. Thiadiazolone derivatives, compositions and uses thereof
WO2024245310A1 (en) * 2023-05-30 2024-12-05 Ningbo Newbay Technology Development Co., Ltd. Thiazolyl or thiadiazolyl amides derivatives and use thereof
WO2024245415A1 (zh) * 2023-06-02 2024-12-05 成都微芯药业有限公司 Polθ抑制剂及其制备方法和用途
WO2024259233A3 (en) * 2023-06-16 2025-02-20 Quantx Biosciences Us, Inc. Fused bicyclic heterocyclic or hetero aryl amide compounds
WO2025011617A1 (zh) * 2023-07-12 2025-01-16 杭州圣域生物医药科技有限公司 并环杂芳环类化合物、其中间体、制备方法和应用
WO2025016391A1 (zh) * 2023-07-18 2025-01-23 南京再明医药有限公司 噻唑并吡嗪类化合物及其应用
WO2025021198A1 (en) * 2023-07-27 2025-01-30 Danatlas Pharmaceuticals Co., Ltd. PolQ DEGRADERS, COMPOSITIONS AND USES THEREOF
WO2025036490A1 (zh) * 2023-08-17 2025-02-20 海思科医药集团股份有限公司 一种DNA聚合酶θ抑制剂及其用途
WO2025045248A1 (zh) * 2023-09-01 2025-03-06 杭州圣域生物医药科技有限公司 联芳环类化合物、其中间体、制备方法和应用
WO2025110780A1 (en) * 2023-11-24 2025-05-30 Daewoong Pharmaceutical Co., Ltd. Novel heterocyclic compounds and pharmaceutical composition comprising the same as dna polymerase theta inhibitors for the prevention or treatment of cancer
WO2025165092A1 (en) * 2024-01-30 2025-08-07 Daewoong Pharmaceutical Co., Ltd. Novel heterocyclic compounds and pharmaceutical composition comprising the same as dna polymerase theta inhibitors for the prevention or treatment of cancer
WO2025223483A1 (zh) * 2024-04-24 2025-10-30 杭州圣域生物医药科技有限公司 并环含氮化合物、其晶型及其制备方法和用途
WO2025223478A1 (zh) * 2024-04-24 2025-10-30 杭州圣域生物医药科技有限公司 并环含氮化合物、其晶型及其制备方法和用途
WO2025223472A1 (zh) * 2024-04-24 2025-10-30 杭州圣域生物医药科技有限公司 一种并环含氮化合物及其中间体的制备方法
WO2025223477A1 (zh) * 2024-04-24 2025-10-30 杭州圣域生物医药科技有限公司 并环含氮化合物、其晶型及其制备方法和用途
WO2025223471A1 (zh) * 2024-04-24 2025-10-30 杭州圣域生物医药科技有限公司 一种并环含氮化合物及其中间体的制备方法

Also Published As

Publication number Publication date
CA3222078A1 (en) 2022-12-15
KR20240044412A (ko) 2024-04-04
AU2022289762A1 (en) 2023-12-14
US20240287080A1 (en) 2024-08-29
CL2023003671A1 (es) 2024-07-12
CO2023017082A2 (es) 2024-04-18
TW202315618A (zh) 2023-04-16
EP4352055A1 (en) 2024-04-17
IL308912A (en) 2024-01-01
JP2024522373A (ja) 2024-06-18
BR112023025245A2 (pt) 2024-02-20
AU2022289762B2 (en) 2025-12-04
MX2023014665A (es) 2024-04-29

Similar Documents

Publication Publication Date Title
AU2022289762A1 (en) O-linked thiadiazolyl compounds as dna polymerase theta inhibitors
AU2021390194B2 (en) Substituted thiadiazolyl derivatives as dna polymerase theta inhibitors
JP6775645B2 (ja) Ｐｉｍキナーゼ阻害剤として有用なチアゾールカルボキサミドおよびピリジンカルボキサミド化合物
AU2019272303B2 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
AU2019246753B2 (en) Novel compounds and compositions for inhibition of FASN
TWI824309B (zh) 作為PI3K-γ抑制劑之雜環化合物
WO2023067515A1 (en) Thiadiazolyl compounds as dna polymerase theta inhibitors
TW202509031A (zh) Ｃｄｋ抑制劑萘啶化合物
CA2851623A1 (en) 5,7-substituted-imidazo[1,2-c]pyrimidines
KR20210151833A (ko) Eed 및 prc2 조절제로서 마크로사이클릭 아졸로피리딘 유도체
TW202440111A (zh) 作為ｗｒｎ抑制劑之雜環化合物
EP4594318A1 (en) Akt1 modulators
KR20230104782A (ko) Bcr-abl 티로신 키나제 억제용 7-아자인돌 화합물
EP4634170A1 (en) Imidazo[4,5-b]pyridine derivatives as pcsk9 inhibitors and methods of use thereof
CN117794927A (zh) 作为DNA聚合酶θ抑制剂的O-连接噻二唑基化合物
CN117083271A (zh) 作为DNA聚合酶θ抑制剂的取代的噻二唑基衍生物
US20250114345A1 (en) Compounds and compositions as cbp/p300 degraders and uses thereof
TW202610638A (zh) 包含維爾納症候群解旋酶抑制劑之組成物及其使用方法
TW201305181A (zh) 酞嗪酮類衍生物、其製備方法及其在醫藥上的應用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22735990

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 805908

Country of ref document: NZ

Ref document number: 2022289762

Country of ref document: AU

Ref document number: AU2022289762

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 308912

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: NC2023/0017082

Country of ref document: CO

Ref document number: MX/A/2023/014665

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2023576009

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 3222078

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12023553373

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: P6003214/2023

Country of ref document: AE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112023025245

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 202317084653

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2022289762

Country of ref document: AU

Date of ref document: 20220609

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: DZP2023001990

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 11202309072U

Country of ref document: SG

WWE Wipo information: entry into national phase

Ref document number: 1020247000980

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2022735990

Country of ref document: EP

Ref document number: 2024100236

Country of ref document: RU

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 523451875

Country of ref document: SA

WWE Wipo information: entry into national phase

Ref document number: 202280054416.4

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2022735990

Country of ref document: EP

Effective date: 20240111

ENP Entry into the national phase

Ref document number: 112023025245

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20231130

WWP Wipo information: published in national office

Ref document number: NC2023/0017082

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 523451875

Country of ref document: SA

WWE Wipo information: entry into national phase

Ref document number: 523451875

Country of ref document: SA

WWW Wipo information: withdrawn in national office

Ref document number: 308912

Country of ref document: IL

WWW Wipo information: withdrawn in national office

Ref document number: 2024100236

Country of ref document: RU

WWR Wipo information: refused in national office

Ref document number: 523451875

Country of ref document: SA